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ABSTRACT 
 
Despite the widespread use of percutaneous vertebroplasty for myeloma and spinal 
metastases, the evidence of its safety, efficacy and cost to the health service is based mainly 
on retrospective studies with short and incomplete follow up.  
 
The aims of this thesis were to: 
 
(1) Perform a systematic review to examine the safety and efficacy of vertebroplasty in 
malignancy, and to determine factors that may be associated with an increased risk of 
complications or reduced efficacy; 
(2) To assess the outcome and complication rate of percutaneous vertebroplasty in a large 
cohort of consecutive patients with myeloma and spinal metastases treated over 9 year 
period and  
(3) To ascertain prospectively the health service cost of vertebroplasty on a cohort of 
consecutive patients with spinal metastases. 
 
 
Results: 
 
Thirty studies were included in the review, of which 8 were prospective. Most report 
performing the procedure under local anaesthesic and continuous fluoroscopic screening, and 
only two centres reported treating more than four vertebrae per session. Five deaths were 
attributable to vertebroplasty, with a further 19 patients suffering a serious complication 
related to the procedure. There is some evidence to suggest that the complication rate may be 
related to the higher cement volume used, although the data is not robust enough for meta-
analysis. Pain reduction ranged between 47-87%, similar to results for osteoporosis. There is 
no correlation between pain reduction and cement volume. 
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In our second study, 128 patients underwent percutaneous vertebroplasty for myeloma (n=41) 
or spinal metastasis (n=87) over a 9 year period. VAS scores fell from 7.75 +/- 1.88 pre-
vertebroplasty to 4.77 +/- 2.69 post vertebroplasty (p=0.001). RDQ scores improved from 
18.55 +/- 4.79 to 13..5 +/- 6.96 (p=0.001). Complications were recorded in three patients : 
cement extension to vena cava (n=1), local haematoma (n=1) and loss of sensation over T1 
dermatome (n=1). The Kaplan-Meier estimate of 5 year survival post-vertebroplasty was 40% 
for patients with myeloma and 25% for those with metastases. 
 
In our final study, the majority of the procedures were performed on an outpatient basis 
(8/11). The median duration of the procedure was 60 minutes (range 40-80 mins) with a 
further 60 minutes spent in the recovery room (10-230 mins). Personnel involved included a 
consultant radiologist, a radiology registrar, four nurses and two radiographers. The average 
cost of vertebroplasty per patient, including consumables, capital equipment, hotel/clinic 
costs and staffing, was £2213.25 (95% CI £729.95). The mean EQ -5D utility scores 
increased from 0.421 pre-treatment to 0.5979 post-treatment (p=0.047). The visual analogue 
scale (VAS) of perceived health improved from a mean to 41.88 to 63.75 (p=0.00537). 
 
Conclusion: 
 
Percutaneous vertebroplasty is safe and effective when performed under local anaesthetic. 
There is good evidence that pain and disability are improved and this effect appears to persist 
for the duration of the patient’s life. Its cost to the health service is acceptable and in line with 
that of other palliative procedures.    
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CHAPTER 1 
INTRODUCTION 
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History 
 
In 1984, a 54 years old French woman attended the University Hospital of Amiens with 
severe cervical pain and C2 nerve root radiculopathy. Her symptoms are chronic, dating 
back years. However, while initial radiographs of the patient’s cervical spine were reported 
as normal in 1979, in 1984 CT and radiographs show the entire C2 vertebra replaced by a 
large lytic mass, with epidural extension. A diagnosis of an aggressive vertebral 
haemangioma was made. The accepted treatment at that time was radiotherapy. This was 
limited, in this case, by the epidural extension and proximity of the lesion to the spinal 
cord. The patient underwent laminectomy and surgical excision of the epidural component 
of the vertebral haemangioma. It was decided that the C2 vertebral body required 
reinforcement – approximately 3ml of bone cement (polymethylmethacrylate, PMMA) was 
injected percutaneously. The patient experienced complete pain relief and the procedure we 
know today as percutaneous vertebroplasty was born1,2!  
 
Development 
 
Vertebroplasty, or augmentation of the vertebral body, has been performed by spinal 
surgeons as an open procedure for decades – usually to strengthen the vertebral body to 
allow spinal instrumentations3. Bone graft or PMMA may be used. The associated 
morbidity associated with such a procedure is not insignificant – and some patients, 
particularly patients with disseminated malignancy, are not suitable candidates for this 
technique.  
 
Galibert et al described their initial experience based on a series of 6 patients and cadaveric 
experiments. The procedure was described as insertion of large bore needles into the 
vertebra and injection of opacified cement under “television surveillance”. Their approach 
evolved from a postero-lateral approach to a transpedicular approach after a case of 
radiculopathy from cement leakage. Encouraged by this new technique, another group of 
clinicians in Lyon performed this “Galibert technique” on 7 patients (4 osteoporosis, 2 
haemangioma and 1 metastasis) and reported good (1) to excellent (6) pain relief 4. The 
procedure remained principally a technique performed in Europe, mainly for painful 
osteolytic vertebral metastases and myeloma, until Jensen described the technique for use 
in the setting of osteoporotic fractures 10 years later in an American radiology journal5. 
That was the start of the explosion of vertebroplasty being performed in the benign setting 
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for which vertebroplasty is now most well known for. The number of procedures increased 
by 72.9% between 2001 and 2010 in the United Sates and up to 70,000-100,000 
percutaneous vertebroplasties were performed in 20116,7. 
 
Various, mainly technical, developments of the procedure have taken place over the years. 
These include better imaging equipment (using CT as well as high resolution biplanar C-
arm fluoroscopy units), various types of introducing needles/trocars to achieve penetration 
of the bone cortex and the availability of cements with differing viscosity and solidification 
time. The technique has evolved too in terms of the approach used (transoral, pedicular, 
para-pedicular, uni- and bi-pedicular) and the judicious use of adjunct venography. 
 
A similar procedure – percutaneous balloon kyphoplasty – was being developed 
simultaneously. This evolved out of the initial clinical impression and cadaveric 
experiments which suggested the cement strengthening effect of axial compression and 
straightening of the curvature of the spine was best achieved by maximal cement filling of 
the entire vertebral body if possible. This involved an additional step of inflating a 
“balloon” within the vertebral body when the trocar is in position to create additional 
“space” for the injection of a larger volume of cement. 
 
The inherent attraction of percutaneous vertebroplasty is multitude - including its 
minimally invasive nature, apparent instantaneous and prolonged effect on pain, the 
stability provided to the fractured vertebral body and its safety record. Vertebroplasty is 
now used in the treatment of osteoporotic, malignant and traumatic spinal fractures8-12.  
 
Its role in spinal metastasis and malignancy continues to evolve. Prior to the advent of 
percutaneous vertebroplasty, treatment options for patients with painful spinal metastases/ 
pathological fractures are radiotherapy or surgery. Surgical options are limited and only 
considered if patients are functionally “good” with a minimum prognosis of 3 months. 
Radiotherapy remains the main stay of therapy for patients with spinal metastasis – but 
pain relief is often delayed. Palliative pain relief is in the form of oral or intravenous 
opioids and bed rest – often in the hospital setting - with not infrequent associated 
morbidity. Minimally invasive procedures are intuitively preferable in patients with 
underlying cancer possibly requiring radiotherapy. This is not least because these patients 
already have a degree of impaired healing, and radiotherapy often needs deferring by up to 
4 weeks post open spinal decompression and vertebral stabilization. Vertebroplasty opens 
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up an alternative means to stabilize the compromised vertebra, with minimal soft tissue 
disruption and healing required, allowing prompt treatment with radiotherapy. This 
revolutionary technique has been shown to be safer and less expensive than open surgery 
in this group of patients with pathological vertebral fractures and limited life expectancy13. 
In addition, with improvements in oncologic treatments, patients with metastatic lesions 
are surviving longer. There is an increased demand to improve quality of life, provide 
palliation and allow these terminal patients to continue with weight bearing activities of 
daily living during the end stages of their disease.   
 
Equipment 
CT and a good quality biplanar fluoroscopic unit are essential in the safe execution of this 
procedure (Fig 1.1, 1.2). Complications are more likely to occur when there is poor 
visualisation of needle placement or cement injection. Digital subtraction angiography 
function on the fluoroscopy unit enables the operator to document needle placement and 
evaluate the trabecular space and epidural veins with venography. CT may be more useful 
in the initial needle placement in the cervical or upper thoracic spine. The injection of 
cement is always performed under continuous fluoroscopic screening. 
 
Figure 1.1:  Patient lying prone in the CT scanner with C arm fluoroscopy to guide 
insertion of trocar. 
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Figure 1.2: Biplanar C-arm fluoroscopy unit. 
 
There are commercially available "vertebroplasty kits" (Figures 1.3, 1.4). They contain 
variations on the theme of the access needle; a hammer for advancement within the 
vertebra; a trocar and catheter for directing and delivering cement within the bone; a 
cement injection device and syringe. Additional equipment required include drills (for 
sclerotic bone lesions), contrast agents (barium sulphate powder for opacification of 
cement and liquid contrast for venography) and related equipment for ablation or 
cryotherapy which are sometimes performed simultaneously to aid/enable vertebroplasty to 
proceed. Local anaesthetic (usually a mixture of short acting lignocaine with a long acting 
agent such as bupivucaine), sedative (midazolam and fentanyl), intravenous antibiotic 
(fluocloxacillin or teicoplanin if penicillin allergic) and bone cement completes the list. 
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Figure 1.3 : Equipment used in percutaneous vertebroplasty: Trocar needles, soft bone 
mallet, cement injection device. 
 
 
 
 
 
Figure 1.4: Types of stylets for needles suitable for vertebroplasty: A: single bevel, B: 
multibevel point, C: diamond point, D: threaded stylet. (Image courtesy of Parallax 
Medical.) 
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Bone Cement - Polymethymethacrylate 
 
The bone cement used is polymethylmethacrylate (PMMA). PMMAis shown to be a safe, 
stable product and has long been used in Orthopaedic procedures anchoring and binding 
surgical prosthesis to the native bone. PMMA was originally used in an "off-label" manner 
as there was no commercially available cement approved specifically for vertebroplasty. 
Marketing clearance was issued in 2005 for PMMA bone cements such as Spine-Fix® 
Biomimetic bone cement and Osteopal ® for the fixation of pathological fractures of 
vertebral body using vertebroplasty and kyhoplasty procedures. It is recommended that the 
use of PMMA be discussed with patients as part of the informed consent process. 
 
Initial experience and ex vivo studies encouraged complete filling of the vertebra, and if 
possible correction of the vertebral body compression. Subsequent studies have shown that 
the clinical effect is unrelated to the volume of cement injected, whereas complications are 
more common when higher cement volumes are recorded14. Current guidelines suggest 
approximately 5ml of cement should be adequate for clinical efficacy. 
 
Multiple PMMA products are available commercially - with polymerisation or 
solidification time as the main discriminator. Powdered PMMA polymer is mixed with 
liquid monomer to produce a solution and barium sulphate then added to the mixture. It 
takes a few minutes for the powder to completely dissolve and relatively quickly the 
mixture begins to thicken and eventually solidifies. Experience is required to time this 
process of alchemy to optimize the time for complete dissolution of the powder/barium 
sulphate admixture and balancing that with speed of drawing up the liquid cement into the 
syringe to allow injection into the spine before the entire batch of cement completely 
solidifies. Too much haste may mean incomplete dissolution of the powdered PMMA 
which separates from the solution, forming a powder plug within the needle. Too slow and 
the mixture solidifies too much to allow drawing up into the syringe and subsequent 
injection. The PMMA powder and liquid vials are often kept in the refrigerator to give 
some latitude to this time sensitive but vital step in the vertebroplasty procedure. 
 
PMMA has been showed to be an excellent substance for use within the vertebral body. It 
is extremely strong and confers strength to the treated bone when axial compression force 
is applied. This stability struts the existing bone trabaculae, minimizing movement of the 
bone fragments and even possibly preventing further microfractures. It is this property 
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which has been proposed as one of the mechanisms by which vertebroplasty works.  
 
The act of combining the powder and liquid PMMA as well as its subsequent solidification 
process is an intensely exothermic process, with temperatures reaching up to 86 degree 
Celsius. This intense heat means care has to be taken during the admixing and injection 
process to prevent thermal injury to the operator. It is also another explanation that has 
been put forward as to why vertebroplasty confers pain relief. Some authors have 
suggested the high thermal energy released during the polymerisation destroys the pain 
nerve endings supplying the periosteum. Others have suggested this high temperature 
destroys the metastatic deposit thereby reducing the mass/pressure within the confined 
space of the vertebra and perhaps also preventing the release of further tumor related pain 
metabolites/mediators11,12,15. Pathological analysis have demonstrated a rim of tumor 
necrosis beyond the extent of PMMA six months post-injection16. 
 
There is incomplete understanding of the mechanism of the analgesic effect behind 
percutaneous vertebroplasty. Perhaps it is the simple act of local anaesthetic infiltration and 
numbing of the sensitive periosteal nerve endings. It is likely a synergistic effect of all of 
the above factors. Alternatively, there is the potent effect of placebo - which has been 
widely ascribed in the literature as the cause in the setting of benign osteoporosis. There is 
however difficult to deny the rapid, often immediate and lasting pain relief reported this 
group of patients with terminal disease. 
 
Needles, Trocars, Catheters, Syringes 
 
Multiple needles, trocars and catheters are available commercially on the market. One of 
the key features to consider when choosing which needle is the type of tip the needle has. A 
multifaceted tip is generally preferred to allow better "purchase" on the bone thus 
improving the ease with which the pedicle is entered. With the advent of performing uni- 
rather than bipedicular percutaneous vertebroplasty, some degree of "steerage" for cement 
deposition is desirable. With this in mind, catheters with side holes rather than tip-end 
single holes are also advantageous in this setting. Type of handle used is a matter usually of 
personal preference. Syringes with 1-5 ml capacity are most frequently used. 
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Departmental set up 
 
The procedure is most commonly performed in an outpatient setting. On the day of the 
procedure, the patient is consented (pre-procedural work up eg coagulation screen, ECG 
and Chest Xrays etc would have been performed prior to the day of vertebroplasty) and 
transferred into the procedural suite.  
 
Percutaneous vertebroplasty may be performed in either the CT or dedicated Interventional 
suite - as long as good imaging equipment is available. The procedure requires, besides the 
operator, two senior radiographers conversant in the functionality of the fluoroscopic and 
CT equipment; three nurses (one for nursing care of the sedated patient, another for 
drawing up and providing the required drugs and kit with a third in recovery room with the 
patient); a "runner" in the room to perform various fetching tasks and finally an assistant 
(usually a registrar) who is scrubbed is desirable though not compulsory.   
 
The patient is placed prone on the table during the procedure. Sedation is administered and 
titrated as required by trained nurses. Oxygen is administered and the patient is under 
constant observation by the nurse via ECG monitors, pulse oxymeters and regular blood 
pressure recordings throughout the procedure.  
 
Post procedure, the patient spends a little time in the recovery room to observe for any 
evidence of immediate complications (such as breathlessness, pain or cardiovascular 
disturbance). If well, he is then transferred to a "day case" ward where he is kept on strict 
bed rest for 2 hours. The patient is discharged home if he is well after this peroid. Some 
patients undergo the procedure as inpatients. This is usually because the patient is referred 
as an inpatient being treated for intractable bone pain, or other social circumstances (eg 
living alone or far away from the hospital).  
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Technique 
The technique has varied little over the last three decades since Galibert et al first 
described it in 198717,18. Minor variations involving the mode of image guidance (CT 
versus fluoroscopy), number of trocars inserted (uni- versus bi-pedicular approach), type of 
needle used to achieve vertebral access, the cement type and use of venography are related 
to the operator preference, fracture morphology and severity. 
 
These patients would have been referred with a CT scan demonstrating osteolytic spinal 
metastases. Pre-procedural imaging usually involves a combination of bone scan, MRI and 
CT scanning of the thoraco-lumbar spine. MRI is useful in confirmation of malignant 
pathology, identification of distant lesions and demonstration of tumour retropulsion into 
the spinal canal. CT is particularly helpful in assessing the posterior cortical destruction of 
the vertebral body and bony destruction of the pedicle. The degree of bony destruction and 
available bone stock will influence the decision to proceed with intervention.  
 
Clinical examination is performed to elucidate whether there is point tenderness over the 
affected vertebra, although clinical benefits have been reported even if vertebroplasty were 
performed remote from the site of pain.  
 
In the majority of cases, the procedure is performed under local anaesthetic with conscious 
sedation using fentanyl, midazolam and lignocaine/bupivicaine. Occasionally the patient is 
unable to tolerate the procedure under sedoanalgesia due to opioid tolerance (or 
intolerance) or inability to lie in the prone position. These patients will be given the option 
of general anaesthesia 
 
Strict anti-sepsis is observed. Intravenous antibiotic cover is given (fluocloxacillin 1g or 
teicoplanin 400mg if penicillin allergic), but antibiotics is not routinely mixed in with the 
cement.  
 
Under fluoroscopic or CT guidance, the target vertebra is identified. The fluoroscopic arm 
is angled to visualise the pedicle - so the oval pedicle is given the scottish terrier dog 
appearance (Figure 1.5). The facet joint is placed medial to the eye of the scottie dog. This 
is slightly easier to visualise in the lumbar compared to the thoracic vertebra on account of 
limitations to the degree of angling possible. After local anaesthetic infiltration of the skin, 
subcutaneous tissues and periosteum, a small incision is made in the skin.  
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Figure 1.5: Oblique view of lumbar spine with scotty dog appearance – image courtesy of 
Dr Yuranga Weerakkody and Dr Frank Guillard et al, Radiopaedia.org. 
 
The needle is placed in the central aspect of the oval pedicle, and enters the bone lateral to 
the superior articulating facet. The needle is advanced carefully, using hand pressure and 
screwing. Sometimes a soft bone mallet is required to aid advancement. In this 
transpedicular approach the needle cannula is advanced towards the anterolateral wall of 
the contra-lateral half of the vertebral body under continuous biplanar fluoroscopic 
screening (Figure 1.6, 1.7).  
 
 
 
Figure 1.6: The trans-pedicular approach. Images courtesy of Medscape.com. 
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Figure 1.7: Under high resolution image guidance - either CT or biplanar fluoroscopy – the 
trocars are inserted safely via the pedicles into the vertebral body : “stay in the ring!”. 
Images courtesy of Dr Richard Edwards. 
 
Some practitioners prefer a "bipedicular" approach, and some situations require the 
positioning of two trocars for adequate access and cement injection. Usually just one trocar 
is sufficient as long as the cannula used allows an adequate degree of angling to direct 
cement flow – through the side holes rather than front opening holes. The unipedicular 
approach has been shown to give just as good a clinical result as a bipedicular approach. 
Two trocars place additional risk to neural structures as well as prolonging the procedure 
time. In addition, the procedure may require more than one sitting if multiple vertebrae 
need treating on account of maximum anaesthesia dose administered.  
 
In the thoracic vertebra, the transpedicular approach is sometimes challenging, owing to 
the convexity of the spine as well as the caliber and bone stock of the thoracic pedicle 
(Figure 1.8). In addition, adequate angling of the fluoroscopic C-arm to achieve the desired 
view of the pedicle is limited by the patient’s body habitus. The “para-pedicular” approach 
is often utilized in this setting. The needle is inserted into the vertebral body adjacent to the 
pedicle, in the costo-vertebral and costo-transverse junction (Figure 1.9). 
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Figure 1.8 : Normal thoracic (left) and lumbar (right) vertebrae. Note the narrow pedicle 
thoracic vertebra compared to the lumbar vertebra. 
 
 
 
Figure 1.9: The para-pedicular approach. (Image courtesy of Prof Wade Wong, JVIR 2003, 
vol 14 (8) p 953-60.) 
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Once the trocar is in position, the cement and barium preparation is mixed to the correct 
consistency (“tooth paste”- like) and drawn up into the cement injection device (Figure 
1.10). The cement is then injected in a controlled but rapid fashion into the vertebra - 
usually no more than 5ml is instilled. This part of the procedure is also performed under 
continuous fluoroscopic screening to ensure the cement stays within the vertebra – 
particularly posteriorly where the neurological bundle is at risk (Figures 1.11, 1.12). 
Cement injection starts from the contralateral half of the vertebral body and the ipsilateral 
half fills as the cannula/catheter is retracted. When cement reaches within 5mm of the 
posterior margin of the vertebral body, stopping and waiting while the cement solidifies is 
all that is required to minimise the risk of epidural space leak. Injection is stopped 
immediately if extravasation is observed. Some practitioners reinsert the introducing stylet 
after the cannula is removed. This is to push any residual cement along the needle tract 
back into the bone as soft tissue cement cast is an irritant and could cause significant pain.  
 
Once the procedure is complete, the patient is instructed to have strict bed rest for two 
hours. If the patient is well after that time, and has home support, he is normally 
discharged home. 
 
Figure 1.10: Drawing up cement (PMMA) mixed with barium sulphate. Image courtesy of 
Dr Richard Edwards. 
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Figure 1.11: Cement injection performed slowly under continuous fluoroscopic screening. 
Image courtesy of Dr Richard Edwards. 
 
 
Figure 1.12: End of procedure view of the cement filled vertebrae. Image courtesy of Dr 
Richard Edwards. 
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Complications 
 
Risk of local complications (eg wound infection) is low as long as an antisepsis technique 
is used and there is no active infection. Local haematoma is sometimes reported, but is not 
a serious issue which usually self resolves without requiring further treatment. 
 
Cement leakage – into the interverbral disc or para-vertebral soft tissues - is the most 
frequently reported complication. It has been reported as occurring in 26-97% of the time, 
but the vast majority are clinically asymptomatic. Rarely, this causes radicular pain from 
nerve root irritation. This is also usually self-limiting - administration of oral analgesia, 
injecting a nerve block or corticosteroid locally may help. Although infrequent, the need 
for surgical decompression has been reported – usually when there is neurological central 
cord compromise from cement leakage into the spinal canal.  
 
Cement embolus is one of the most serious of the reported complications – occurring in 
approximately 5% of cases performed. This is associated with the use of larger cement 
volumes under high pressure, resulting in the extravasation of cement into draining 
vertebral veins. Deaths from pulmonary cement embolus have been reported. 
Cardiovascular and respiratory compromises have also been reported. This may relate to 
fat embolism or a systemic reaction to PMMA.  
 
During the early years of vertebroplasty, there was concern with regards to a higher 
incidence of complications when performing vertebroplasty on patients with metastatic 
bone disease. This resulted in a period where venography was advocated prior to the 
injection of cement (Figure 1.13). Venography has not been shown to reduce the incidence 
of complications, and could obscure visualisation of the cement if it fails to clear, and is 
therefore no longer routinely performed. Venography is still useful if there is concern 
regarding vascular tumor neoangiogenesis, to help delineate large draining vessels which 
need to be avoided to prevent cement embolus. 
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Figure 1.13: Venography delineating draining veins. 
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Bone metastasis 
 
It has been estimated that 1.5 million people world wide have bone metastasis19. Of the 
various bones, the spine is the most common site involved20. Breast, lung and prostate 
cancer are the most common primary malignancies. Autopsy series found bone metastases 
in 27% of patients with carcinoma. Bone metastases have also been reported in 47-85% of 
patients dying of breast cancer, in 33-85% of patients with prostate cancer and 32-60% of 
lung cancer21. Osseous metastasis may be the first presentation in about 20% of patients 
with systemic cancer22. 
 
The primary cancer and degree of disease dissemination (burden of disease, visceral versus 
bone metastasis) are important prognostic indicators. Median survival following detection 
of bone metastases vary greatly between different cancers 23 (Table 1.1). 
 
Another important prognostic indicator is initial functional status24, 25. The ability to 
ambulate is a favorable prognostic sign, while loss of sphincter control is a poor prognostic 
indicator and mostly irreversible. Most ambulatory patients remain ambulatory after 
treatment while few paraplegic patients are able to walk after treatment (treatment outcome 
= neurological impairment before treatment26. Thirty percent of patients who present with 
weakness progress to paraplegia within a week. The likelihood of neurological recovery is 
poor when paraplegia has been present for 24 hours27. A multidisciplinary approach is 
needed to best serve a patient. Advances in chemotherapy, hormonal therapy, surgery and 
radiation therapy have also improved survival28.  
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 Median Survival  5 year survival (%) Notes 
Breast cancer 1-2 years 13% Sub group  
(bone only 
metastasis) median 
survival is 4 years 
Prostate cancer 1-2 years 17%  
Lung cancer 3 months 2%  
Multiple myeloma 2-3 years   
Colorectal cancer  13 months   
Cervical cancer   Almost all dead 
within 18 months  
Renal cell cancer 1 year 30% if solitary 
bone metastasis 
 
 
Table 1.1 : Survival of patients with bone metastases from various primary cancers. 
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Treatment 
 
The philosophy of management of patients with bone metastasis is by nature palliation. 
This encompasses preservation of function, pain control, spinal stability and, if possible, 
preventing the development of further pathological fracture.  
Medical therapy: 
The general health of the patient should be considered. Formulated standards for cancer 
pain management exists and has helped improved the quality of life for terminally ill 
patients. Hypercalcaemia is not uncommon in patients with spinal metastasis and can be 
controlled with bisphosphonates, steroids, hydration. Systemic chemotoxic agents may 
have a role, typically in the asymptomatic patients, and hormonal therapy may be 
beneficial in endocrine dependent primary malignancies like breast and prostate cancer. 
Newer agents like monoclonal antibodies (Denosumab) have been designed to attack the 
RANK ligand, reducing bone removal, and have been shown to decrease the incidence of 
pathological fractures, spinal cord compression, severe pain requiring radiotherapy or 
surgery and hypercalcaemia29. 
Radiotherapy : 
Radiotherapy is the mainstay of treating spinal metastasis – particularly in lymphoma, 
seminoma, myeloma, prostate and breast cancer. Advances in imaging technology and CT 
planning has allowed the safe delivery of large doses of highly focused beams of radiation 
in stereotactic radiosurgery (SRS). Indications of SRS includes limited disease (1-3 
metastases), no more than two contiguous vertebral bodies, limited and/or controlled 
systemic disease, good performance status and an anticipated survival of greater than 3 
months30. This has the advantage over conventional radiotherapy of (1) avoiding 
unnecessary irradiation of bone marrow (2) does not interfere with on going chemotherapy 
(3) single day out-patient treatment (particular advantageous in patients with short life 
expectancy) (4) effective salvage of previously irradiated areas, (5) treating radio-resistant 
histologies eg melanoma, sarcoma, renal cell carcinoma, (6) providing possible rapid onset 
and longer duration of pain control, (7) non-invasive29. Conventional external beam 
radiation is a reasonable option for patients with life expectancy of less than 3 months.  
Response to radiotherapy in general is related to the radiosensitivity of the primary tumor 
being treated. Poorer outcomes are seen with radioinsensitive histologies eg hepatocellular 
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carcinoma, gastro-intestinal tract cancer, lung cancer. Pain palliation is seen in 57-77% of 
patients treated with conventional radiotherapy31. There is symptomatic pain relief in 85% 
treated with SRS, and 70% of responders did so in 2 weeks and 90% in 2 months. About 
half of the patients with neurological impairment get some recovery. Overall local control 
and radiographic response after SRS is reported excellent in 80-90%32.   
Radiotherapy in combination with surgery has also been shown to be beneficial with a 
significant chance of stabilisation and improvement of neurologic outcomes, with reported 
local control rate of 94%33. However radiotherapy has to be deferred between 1- 4 weeks 
post surgery to enable adequate healing. Comparable local control rates of 92% has been 
reported in a study into SRS after vertebral cement augmentation34.The need for delay is 
much less in these minimally invasive procedures. 
Surgery: 
The benefit of surgery is the ability to provide mechanical stability to the spine, pain relief 
and maintenance of neurological function35. Traditional posterior decompressive 
laminectomy has been shown to have no advantage over radiotherapy alone. It also 
destabilises the posterior column, and the anterior approach for spinal stabilisation and 
decompression is now preferred36. New data suggests that aggressive surgery in the form 
of circumferential spinal cord decompression by means of vertebrectomy, reconstruction 
and stabilization has better outcome than traditional laminectomy37. A randomised control 
trial comparing direct decompressive surgical resection followed by adjuvant radiation 
with conventional radiation alone demonstrated the surgical group retained ambulatory and 
sphincter function significantly longer than the radiation group. Survival was longer and 
56% of patients in the surgical arm regained the ability to walk compared to 19% of the 
radiation cohort38.  
Various scoring systems exist to assist in the stratification and decision making process to 
guide therapy choice. These include the Tokuhashi (revised) prognostic score and 
Harrington’s Classification39. Patients who have a Tokuhashi score of ≤ 5 generally die 
within 3 monthsm whereas those with total score of ≥ 9 survive an average of 12 months or 
more (Table 1.2 and 1.3).  
Tokuhashi et al. recommended excisional surgery for patients with a good prognosis 
(Tokuhashi score of 12–15), palliative surgery for most patients with an intermediate 
prognosis (score of 9–11), and conservative management for patients with a score of 8 or 
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less. 
Surgery is palliative for the majority of patients with spinal metastases and the assessment 
of overall quality of life is perhaps more relevant than physical scores and neurological 
outcome measures. The use of quality of life measures for all patients undergoing surgery 
is advocated. The greatest improvements are in the domains of pain, but also non-specific 
symptoms, such as tiredness, nausea, anxiety and appetite may improve after surgery. The 
Euroquol EQ-5D is an assessment tool used in assessing quality of life patients with 
metastatic disease. This is a simple 5-point validated questionnaire that is simple for 
patients to complete and investigators to interpret40.  
Surgery in the setting of spinal metastasis has a complication rate of up to 40%37,41. 
Moreover, when comparing with minimally invasive procedures such as vertebroplasty, 
surgery has been shown to be more expensive and patients more likely to die and less 
likely to be discharged home13.  
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Table 1.2: Revised Tokuhashi prognostic score 28 
 Score 0 Score 1 Score 2 Score 3 Score 4 Score 5 
Karnofsky’s 
performance 
10-40 50-70 80-100    
Extraspinal 
metastasis 
3 or more 1-2 0    
Vertebral 
metastasis 
3 or more 2 1    
Visceral 
metastasis 
Unresectable Resectable None    
Primary site  Lung Liver Other Kidney Rectum Breast 
Palsy Frankel A,B Frankel 
C,D 
Frankel E    
Scores for the six individual criteria above are added to provide a total score up to a 
maximum of 15 
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Table 1.3: Harrington’s Classification of spinal metastases39  
1. No significant neurological involvement. 
2. Bone involvement without collapse or instability. 
3. Major neurological impairment (sensory or motor) without significant involvement 
of bone. 
4. Vertebral collapse with pain due to mechanical causes or instability, but without 
significant neurologic compromise. 
5. Vertebral collapse with pain due to mechanical causes or instability combined with 
major neurologic impairment. 
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Malignant Spinal Cord Compression 
Spinal cord compression is the dreaded complication of spinal metastasis, and occurs in 
about 5-10% of patients with cancer and 20% of patients with spinal metastasis28. Without 
treatment, the inevitable outcome is paraplegia and limited survival42. Vertebroplasty does 
not yet have a role in the immediate management of these patients with rapidly 
deteriorating neurology . The current management algorithm for malignant spinal cord 
compression is : steroids, surgical decompression followed by radiotherapy. There are 
studies currently investigating the role of SRS only in this setting29.  
 
Prophylaxis 
 
Patients undergoing radiotherapy have been shown to have an increased risk (20 – 39%) of 
vertebral fracture of the spine. Although the cause may be related to a combination of 
factors including disease progression, patients most at risk were those who were aged 55 
years, with pre-existing spinal fractures and pain, larger lytic lesions and poorer 
performance status.  There is some data suggesting prophylactic vertebral augmentation of 
those most at risk reduces the incidence of vertebral collapse – and thus potentially 
reducing the incidence of spinal cord compression43-45. However other studies have shown 
no improvement in proportion of ambulant patients post vertebroplasty46.  In the 
osteoporosis, prophylaxis has also been shown to have no preventive effect on subsequent 
vertebral fracture rate21. Although no concrete evidence to the role of prophylactic 
vertebroplasty in the prevention of spinal cord compression, the economic assessment 
performed by NICE indicates that vertebroplasty (with radiotherapy) was the dominant 
strategy in preventing paraplegia and improving QALY when compared to no treatment for 
ambulant patients47. 
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Patient selection 
 
Diagnosis of vertebral metastasis: 
 
Pain 
 
Any patient with spinal metastasis and back pain is suitable for consideration of 
percutaneous vertebroplasty. Noctournal or rest pain are thought cardinal signs. However, 
up to a third of patients with breast or prostate cancer are free from pain23. While in other 
patients, the symptoms preceed any detectable evidence of bone metastasis. 
 
Biochemical tests 
 
Serum alkaline phosphase is often elevated in skeletal metastasis from prostate and breast 
cancer. However, its sensitivity and specificity is unreliable and certainly not 
pathognomonic of bone metastasis. 
 
Radiologic Evaluation 
 
Xrays are an insensitive tool in the detection of bone metastasis – 30-50% bone loss has to 
be present before any findings are apparent on Xray. With it low positive predictive value, 
Xrays are not routinely used in the investigation of possible spinal metastasis.    
 
Bone scintigraphy is much more sensitive at detecting spinal metastasis – being able to 
pick up lesions as small as 2mm and up to 18 months before any Xray abnormality is 
visible17 (Figure 1.14). A slight disadvantage is the relative insensitivity to osteolytic bone 
metastasis (eg myeloma, thyroid and renal cancer) and limited localization – although this 
has improved with the advent of SPECT CT. 
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Figure 1.14: Bone scan - vertebral, rib and sternal metastasis 
 
Often these patients would have had numerous antecedent CT of the spine as part of their 
care, in staging and re-staging of their disease and response to treatment. The finding of 
bone destruction is less sensitive than bone scan or MRI at detecting bone metastasis, but is 
much more specific. An osteolytic lesion in the spine, particularly if it is new, in the setting 
of underlying cancer is most likely the result of a metastatic deposit. Lesions as small as 3-
5mm are detectable by CT and adjacent pathological soft tissue change adds weight to the 
diagnosis (Figure 1.15). Care should be taken not to confuse benign conditions (eg 
haemangioma, bone island, primary bone tumors, osteomyelitis and even Paget's disease) 
with metastatic deposits. If there is any uncertainty or concern regarding further occult 
disease, complementary MRI spine or bone scan is usually helpful in clarifying the 
situation.  
   Figure 1.15: A lytic bone metastasis in the vertebral 
body. Non-Hodgekin’s lymphoma DV11. 
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MRI has the greatest sensitivity (98%) and specificity (99%) with an overall accuracy of 
98.7%49. It has been shown to be superior in evaluating the neural elements and detecting 
multiple levels of vertebral involvement and is the imaging modality of choice in 
diagnosing spinal metastasis50,51 (Figure 1.16).  
 
PET/CT has become the initial imaging tool for many malignancies52. FDG-PET has a 
higher sensitivity, specificity and negative predictive value when compared to a bone 
scan53. 
 
Bone biopsy is good practice to confirm diagnosis. Patients with sclerosing bone 
metastasis from underlying breast or prostate cancer pose a slight technical challenge but 
are also suitable for consideration for percutaneous vertebroplasty. 
 
 
Figure 1.16: MRI (T1W, T2W and STIR) demonstrating tumor deposit and grade III 
compression fracture. Note tumor involvement of pedicle. The tumor/retropulsed bone 
complex indents the spinal cord. 
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Referral 
 
Pain can be easily assessed with the Brief Pain Inventory or a Visual Analogue Scale. 
Performance status can be evaluated using the Eastern Cooperative Oncology Group or the 
Karnofsky Performance Scale. The primary tumor site is an important predictor of survival 
and prognosis28.  
 
Traditionally, it is only when patients experience refractory pain not managed by prolonged 
inpatient stay (often bed bound), post-radiotherapy or resistant to high dose oral opioids 
were they referred for vertebroplasty. In our experience, early referral may result in quicker 
return to mobility, discharge from hospital and less opioid related complication. 
Increasingly patients are being referred pre-radiotherapy as an adjunct to the management 
of their disease related pain.  
 
The issue of clinical benefit - both the onset and duration - as well as cost effectiveness 
inevitably come into any debate of how these patients with effectively disseminated 
terminal disease are selected for any form of treatment. However, the value of palliative 
pain relief and return of function in these patients with limited life expectancy is not to be 
understated, although much more difficult to quantify24. 
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Contra-Indications 
 
Patients with uncontrolled bleeding disorders, fracture/tumor retropulsion into the spinal 
canal causing spinal cord compression and active infection are not suitable candidates for 
percutaneous vertebroplasty. Posterior wall distruction, spinal canal narrowing but no cord 
compression and vertebral plana are now relative contra-indictations (Figure 1.17). 
Provided there are no neurological symptom, vertebroplasty could proceed, but the 
procedure may need to be preceded by or performed with simultaneous tumor ablation. 
Allergy to local anaesthesic, could be circumvented by performing vertebroplasty under 
general anaesthesia - although this will need to be balanced against the risks of anaesthesia 
to the patient's underlying health state. 
   
Figure 1.17: Bone scan, CT same patient demonstrating the degree of bone destruction, 
remnant bone stock and canal narrowing by the tumor/retropulsed bone.  
 
Sclerotic bone metastasis are technically more challenging than lytic lesions. Strategies for 
coping with this include using a special drill to achieve needle penetration into the 
metastatic deposit and cryoablation of the tumor to allow injection of cement into the 
metastasis and vertebral body.  
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Body of evidence 
 
There is increasing high level clinical evidence investigating the role of vertebroplasty in 
benign osteoporosis. These include the randomized controlled studies by Buchbinder 
(vertebroplasty no better than sham procedure), INvestigational Vertebroplasty Efficacy 
and Safety Trial (INVEST: improvement in function was better and sustained in 
vertebroplasty group when compared to local anaesthetic group)VERTOS studies 
(VERTOS II demonstrating cost effectiveness and better short term pain control for acute 
osteoporotic wedge fractures compared to conservative management; VERTOS IV results 
awaited comparing vertebroplasty to sham procedure in acute osteoporotic fractures) 
54,55,56,57,58.  Results by and large have been controversial, suggesting that local anaesthetic 
or sham procedure may be as effective as percutaneous vertebroplasty (Table 1.4). 
 
Despite its widespread use, little good quality information exists in the literature regarding 
the role of vertebroplasty in the setting of spinal metastasis. The body of evidence is 
largely composed of small, retrospective observational studies with short follow up, which 
suggest percutaneous vertebroplasty is safe and effective in the management of spinal 
metastasis with minimal serious complications. This may in part be related to the nature 
and inherent heterogeneity of the underlying patient population making recruitment of 
sufficient adequately matched patients a challenging prospect.  
 
There is therefore a need to scrutinise the studies examining percutaneous vertebroplasty in 
spinal metastasis and determine based on the existing available information the efficacy 
and safety of vertebroplasty in patients with spinal metastasis. There is also a need for 
large, prospective studies with longer follow up to clarify its role in this patient group. 
Finally, the cost of the procedure to the Health Service has not been investigated. In 
addition there is no real evidence relating to cost and quality of life for these patients.  
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Trial No. 
patients 
Comparing  Primary outcome Secondary outcome 
Buchbinder 
2009 
N=78 Vertebroplasty 
vs  
Sham procedure 
Overall pain : No 
significant 
difference in change 
from base line 
between VP and 
placebo.  
Mean reduction of 
pain : -2.6 +/- 2.9 
(VP) and -1.9 +/- 3.3 
(P)  
Quality of Life 
(QUALEFFO) and 
R-M Disability 
score: 
No significant 
difference between 
groups. 
INVEST 
2009 
N=131 Vertebroplasty 
vs 
Local 
anaesthetic 
Overall pain: No 
significant 
difference at 3 days, 
1 week and 1 month, 
although the pain 
reduction was 
clinically significant  
Co-primary 
outcome (RMDQ 
score): 
No significant 
difference between 
control and VP.  
VERTOS 
 
N=202 Vertebroplasty 
vs 
Conservative 
management 
Pain: 
Significant reduction 
in pain at  1 month (-
2.6) and 1 year (-
2.0) 
QUALEFFO and 
RDQ scores: 
“Significant 
improvement”   
 
Table 1.4: Summary of trials of percutaneous vertebroplasty for painful osteoporotic 
fractures. 
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Aims: 
 
 
1. To perform a systematic review to determine the safety and efficacy of 
percutaneous vertebroplasty in patients with spinal metastases. 
 
 
2. To assess the outcome and complication rate of percutaneous vertebroplasty in a 
consecutive series of patients with myeloma and spinal metastases over a 9 year 
period. Outcome included short term effects on pain and disability as well as 
median survival for those with myeloma and metastases from other primary 
cancers. Baseline data and results from questionnaires was gathered prospectively.  
 
 
3. To assess the cost to the Health Service of percutaneous vertebroplasty in a 
prospective series of patients with spinal metastases. In addition we determined the 
cost per quality adjusted life year (QALY) for those with myeloma and spinal 
metastases from another primary cancer. 
 
  
34 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
Safety and Efficacy of Percutaneous 
Vertebroplasty in Malignancy : A 
Systematic Review. 
35 
 
Introduction: 
 
Percutaneous vertebroplasty was first described by Galibert and colleagues in 1987 as a 
minimally invasive treatment of painful vertebral haemangioma1. Since then, the use of 
vertebroplasty has expanded to include treatment for osteoporosis, spinal metastasis and 
rarely in traumatic fractures. Vertebroplasty for malignancy is attractive as an adjunct to 
radiotherapy or chemotherapy due to its rapid efficacy in patients with intractable pain.  
 
Vertebroplasty has been shown to be safe with few complications in the setting of 
osteoporosis54,55. Concern remains regarding an apparent increase in complication rates for 
vertebroplasty in cancer patients. This is based mainly on published case series and 
technical review articles reporting neuropathy requiring emergency decompression and 
procedure related mortality10,59. The suggested reasons for an increased risk to patients 
with metastases include the loss of cortical integrity and tumour angiogenesis59. Critical 
evaluation of the current evidence is needed to quantify the efficacy and safety of the 
procedure in the context of malignancy. 
 
The aim of this study was to examine the safety and efficacy of vertebroplasty in 
malignancy, and to determine factors that may be associated with an increased risk of 
complications or reduced efficacy. Data was extracted and compiled based on available 
peer-reviewed publications to address these issues. 
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Methodology: 
 
MEDLINE (OVID), EMBASE (OVID) and CENTRAL databases were searched from 
inception to April 2010. No restrictions were placed on publication date within these 
databases. This review included English language studies only. 
 
A search strategy was developed in collaboration with the University Subject Librarian 
using a combination of Medical Subject Headings (MeSH) and text words. Text words 
were truncated and were used to describe the intervention and disease; “vertebroplasty”, 
“cementoplasty”, “malignancy”, “oncology” and “metastasis” (Appendix 2). The search 
was tailored to each database. Search filters were used to target particular study types. The 
search output was reviewed to ensure the strategy was detecting references that were 
relevant. 
 
All clinical trials and observational studies where patients with malignant disease 
underwent percutaneous vertebroplasty were included. There was no requirement for 
studies to have a comparator intervention.  
 
Studies were included if they reported on at least one of the following outcomes: technical 
efficacy, pain relief, functional quality of life, safety, cement leakage, complication. 
Complication was defined as any event requiring medical or surgical intervention. Review 
articles and studies investigating percutaneous vertebroplasty in patients with non-
malignant disease such as osteoporosis were excluded. Studies which included patients 
with benign and malignant disease were included if results were reported separately for 
each group. Similarly, if a study combined the use of percutaneous vertebroplasty with 
another intervention such as radiotherapy or surgery it was included if the data was 
reported for each intervention. 
 
Two reviewers independently scanned the titles and abstracts of all references downloaded 
to the bibliographic software to identify potentially relevant articles. For all references 
which met the inclusion criteria a copy of the full article was retrieved. References which 
did not meet the inclusion criteria were coded according to the exclusion criteria. Any 
disagreement at the screening or retrieval stage was resolved by discussion; a third 
reviewer was available to be consulted, but never used.  
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Where appropriate, authors were contacted to clarify results between the malignant and 
benign patient cohort when the results were not explicit.  
 
Data were collected for each included study using a pre-designed data extraction form. 
Information on study participants, the technical aspects of the intervention, the outcomes 
measures and follow-up was recorded for each study. Study participant information 
included age, gender and description of malignancy (type and stage of disease) and the 
indication for percutaneous vertebroplasty.  Technical information included cement volume 
injected, type of anaesthetic used, type of image guidance (CT or C-arm image 
intensifier/fluoroscopy), the approach and the level and number of vertebra treated. The 
outcomes and outcome measures for the study were noted. These included quantifiable 
measures of pain such as the visual analogue pain scale (VAS), analgesia used and quality 
of life measures such as ECOG performance status (Eastern Cooperative Oncology 
Group). Complications included cement leakage (asymptomatic and symptomatic), 
increased pain, wound infection, haematoma, decompression surgery, 
haemopneumothorax, pulmonary embolus or death. Serious complications were defined as 
those that were potentially life threatening (eg deep venous thrombosis [DVT], 
symptomatic pulmonary embolus, neuropathy requiring surgical decompression, 
haemothorax and haematoma requiring surgical decompression). The length of study 
follow up and patient drop out were recorded. 
 
 
Data Synthesis and Analysis  
 
Results were extracted where possible as raw numbers, plus any summary measures with 
standard deviations and confidence interval. VAS pain scores were adjusted to a 10-point 
scale where necessary60,61. Data was summarised according to outcomes of interest. Meta-
analysis was planned if appropriate data was available; if not, results were tabulated. 
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Results: 
 
Seven hundred and sixty abstracts were generated in the initial search. Forty-five papers 
were retrieved for evaluation, of which 29 were included for this review. Hand searching 
identified one additional study (Fig 2.1). One author was contacted for clarification of data 
between benign and malignant cohort, and the study was included60. Summary of these 
studies is presented as a table of evidence (Table 2.1).  
 
Of the 30 studies included, there was one randomised controlled trial, seven were 
prospective and 20 were retrospective studies. The study designs of two were unclear. The 
selection process is summarised in Figure 2.1. 
 
The total number of patients undergoing vertebroplasty included in this review was 987. 
Mean age of patients varied between 45 and 72 years in the 30 studies. The main indication 
for vertebroplasty was pain. The procedure was performed predominantly for spinal 
metastases, however eight studies reported outcome for myeloma patients only65,68-70,75-
77,81. 
 
Most procedures were performed under local anaesthesia and continuous fluoroscopic 
screening with a C-arm image intensifier. Although general anaesthesia was preferred by 
many for treatment of cervical lesions, only one author used it exclusively70.  
 
The most commonly treated vertebral levels were thoracic and lumbar. Two studies 
described vertebroplasty for cervical spinal lesions only in nine patients70,81. Most studies 
treated between one to four vertebrae per session, with only two treating more than 4 
vertebrae simultaneously 67,77. 
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Figure 2.1: Study selection flow diagram. 
 
 
 
 
 
 
 
 
 
Abstracts identified by search strategy  (n=760) 
Not meeting inclusion criteria on abstract/title (n=715) 
Reports of studies retrieved for detailed evaluation (n=45)  
Total studies included in systematic review (n=30) 
Studies with usable data (n=29) 
Study included from hand search (n=1) 
Not meeting data criteria (n=16) 
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Author 
(Year) 
Study Type Patient / 
Vertebrae 
No. 
(Level) 
 
Age 
(yrs) 
Mean 
Myelo
ma or 
Metast
asis 
Technical 
Local (LA) 
or 
General 
anaesthetic 
(GA) 
Cement 
Volume 
 (ml) 
Outcome 
Measure 
Complications Follow up 
(mean) 
Cotten11 
(1996) 
Prospective 37 /  40 
(C/T/L) 
58 Mixed LA & 
Fluoroscopy 
C :2.5 
T : 5.5 
L : 7.0 
Pain 
(McGill-Melzack) 
CT % filling 
Leaks 
Neuropathy (3) 
 
4 months 
Weill12 
(1996) 
NA 21 /  28 
(C/T/L) 
61 Metasta
sis 
Mainly LA & 
Fluoroscopy 
NA Analgesia 
change 
Stability 
 
Neuropathy (2) 
Hyperalgia (2) 
Dysphgia (2) 
7 months 
Martin61 
(1999) 
Retrospective 22 / -  
(T/L/S) 
67 Mixed GA mainly & 
Fluoroscopy 
NA Pain relief 
CT % filling 
Leak 
DVT (1) 
Death (2) 
14 months 
Barr62 
(2000) 
Retrospective 8 / 13 
(C/T/L) 
69 Mixed GA & LA 
CT & 
Fluoroscopy 
T : 2-3 
L : 3-5 
Pain relief  
 
Stability 
 
None reported 
 
10 months 
Table 2.1: Table of evidence. 
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Alvarez45 
(2003) 
Retrospective 21 / 27 
(C/T/L) 
58 Metasta
sis 
LA & 
Fluoroscopy 
 4.2 Pain (VAS) 
Gait 
Function  
Radiculopathy (1) 5.6months 
Fourney46 
(2003) 
Retrospective 34 /   - 
(T/L) 
64 Mixed GA & LA 
Fluoroscopy 
2-8 Pain (VAS) 
Analgesia change 
Function (Frankel) 
Leaks 
None reported 4.5 
months 
Martin63 
(2003) 
Retrospective 32 /  87 
(T/L) 
63.5 Mixed GA mainly 
Fluoroscopy 
NA Pain (VAS) 
Leak 
 
None reported NA 
 
 
 
Mousavi64 
(2003) 
 
Retrospective 9 /  14 
(T/L) 
60 Metasta
sis 
LA & 
Fluoroscopy 
 
NA 
Pain (Edmonton) 
Leaks 
Neuropathy (1) 1 week 
Chow60 
(2004) 
Prospective 10 /  - 
(T/L) 
63 Metasta
sis 
LA &  
Fluoroscopy 
3-6 Pain (Edmonton) 
Analgesia change 
Function(Townsend) 
Neuropathy (1) 3 months 
Diamond65 
(2004) 
NA 7 / 14 
(T/L) 
69 Myelo
ma 
LA & 
Fluoroscopy 
1-6 Pain (VAS) 
Analgesia change 
Function 
Vertebral height 
None reported 6 weeks 
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Shimony66 
(2004) 
Retrospective 50 /  129 
(T/L) 
62.7 Mixed LA & 
Fluoroscopy 
NA Pain (VAS) 
Function 
 
Increased pain (7) 3 months 
(median) 
Barragan- 
Campos67 
(2006) 
Retrospective 117/  304 
(C/T/L) 
58 Mixed GA 
(preferred) 
Fluoroscopy 
4.5 Complications Radicular pain (4) 
PE (2) 
Death (1) 
30 days 
Kose68 
(2006) 
 
Retrospective 16 / 28 
(T/L) 
63.7 Myelo
ma 
LA & 
Fluoroscopy 
3.3 Pain (VAS) 
Analgesia use 
NA 1 year 
Ramos69 
(2006) 
Prospective 12 / 19 
(T/L) 
66 Myelo
ma 
La & 
Fluoroscopy 
NA Pain (VAS) 
Function (ECOG) 
 
None reported 3.2 yrs 
Pflugmacher70 
(2006) 
Prospective 5 / 12 
(C) 
60 Myelo
ma 
GA & 
Fluoroscopy 
1.8 Pain (VAS) 
Function 
(NPDI, CSFS) 
Spinal height stability 
None reported 12 months 
 
 
 
Calmels71 
(2007) 
Retrospective 52 / 103 
(C/T/L) 
54 Metasta
sis 
LA & 
Fluoroscopy 
4.5 Pain relief 
Leaks 
Neuropathy (3) 
Radicular pain (1) 
PE (2) 
Haemothorax (1) 
 
17 months 
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Anselmetti72 
(2007) 
 
Prospective  12  /   38 
(T/L) 
72.2 Mixed LA & 
Fluoroscopy 
5 Pain (VAS) 
Function(Oswestry) 
Leaks 
None reported 6 months 
Barbero73 
(2008) 
 
 
Retrospective 37 /  53 
(NA) 
71.4 Mixed LA & 
CT & 
Fluoroscopy 
2 Pain relief 
(Asymtomatic PE) 
No serious 
complications 
7 months 
Caudana74 
(2008) 
Retrospective 38 /  62 
(T/L) 
62 Mixed LA & 
CT & 
Fluoroscopy 
5 Pain (VAS) 
Analgesia use 
Mobility 
NA 6.4 
months 
Masala75 
(2008) 
 
Retrospective 64 /  198 
( T/L ) 
 
71 Myelo
ma 
LA & 
Fluoroscopy 
NA Pain (VAS) None reported 6 months 
McDonald76 
(2008) 
Retrospective 67 /  114 
(T/L) 
66 Myelo
ma 
LA & 
Fluoroscopy 
NA Pain (VAS) 
Function (Roland-
Morris) 
Subjective outcome 
None reported 1 year 
Thang77 
(2008) 
Retrospective 28 / 117 
(T/L/S) 
65 Myelo
ma 
GA usually & 
Fluoroscopy 
3.1  Pain (VAS) 
Opiate use 
Function (ECOG) 
 
Hyperalgia (1) 
Shortness breath/ 
chest pain (2) 
41 month 
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Trumm78 
(2008) 
Retrospective 53 / 86 
(C/T/L/S) 
62 Metasta
sis 
LA & 
CT 
C : 1.5 
T : 3  
L : 3.5 
S : 6  
Pain (VAS) 
Analgesia use 
No serious 
complication 
9.2 month 
 
 
 
 
Tseng79 
(2008) 
Retrospective 57 / 78 
(C/T/L) 
65 Metasta
sis 
GA preferred 
& 
Fluoroscopy 
5  Pain (VAS) 
Analgesia use 
Neuropathy (3) 
Haematoma (2) 
Death (4) 
NA 
Lee80 
(2009) 
Retrospective 19 / 34 
(T/L) 
70 Metasta
sis 
GA preferred 
& 
CT preferred 
NA Pain relief 
Function (ECOG) 
Hyperalgia (1) 12 months 
Mt’Alverne81 
(2009) 
Retrospective 4 / 5 
(C)  
45 Myelo
ma 
LA & 
Fluoroscopy 
2.3 Pain relief 
Vertebral filling 
None reported 27 months 
Chen82 
(2009) 
Retrospective 31/42 
(T/L) 
67 Mixed GA & 
Fluoroscopy 
NA Pain (VAS) 
Quality of Life 
improvement  
(Karnovsky) 
None reported 12 months 
Kobayashi83 
(2009) 
Prospective 33/42 
(T/L) 
62 Mixed LA & 
fluoroscopy 
and CT 
fluoroscopy 
3.5 +/-
1.8 
Safety 
Pain relief (VAS) 
 
None reported 6 months 
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Yang84 
(2009) 
Randomised 
Controlled 
Trial (VP vs 
VP + 
Interstitial 
I125 
40/64 
(T/L) 
58.7 Metasta
sis 
LA & 
Fluoroscopy 
T: 4.5  
L: 6  
Pain relief (VAS) 
Quality of Life 
improvement 
(Karnovsky) 
None reported 12 months 
Saliou85 
(2010) 
Retrospective 51/74 
(C/T/L) 
62.5 Mixed LA or GA & 
Fluoroscopy 
NA Pain relief 
Vertebral filling 
Symptomatic cauda 
equina 
 
60 months 
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Complications: 
 
Five deaths that could be attributed to vertebroplasty were reported in 3 studies61,67,79. Two 
were from chest infections following general anaesthesia, one from a cement pulmonary 
embolus and two from sepsis after emergency spinal decompression. A further two patients 
died of medical disease during hospitalisation – one of ischaemic heart disease and one of 
respiratory failure71.  
 
Nine studies reported serious complications in 20 patients 11,12,60,61,64,67,71,79,85, 12 had 
neuropathy and one had a haematoma - all requiring emergency decompression surgery. 
One patient had a haemothorax, while another had a deep venous thrombosis and four had 
symptomatic cement pulmonary emboli (Table 2.2). 
 
Twelve studies reported both mean cement volume used and complications67,70-73,77-
79,81,83,84. There is some indication that a cement volume of greater than 4ml results in an 
increased number of complications (Tables 2.3). 
 
All studies reported small volume, local, intra-discal or paravertebral cement leaks. 
However most were asymptomatic. No increase in complication was evident in series 
performing vertebroplasty on vertebrae with a posterior cortical breach. General 
anaesthetic was used preferentially only in 8 studies61,63,67,70,77,79,80,82, and thus a statistical 
association between the type of anaesthesia with complication rate could not be examined. 
However, the authors in the 3 studies that reported deaths all preferred the use of general 
anaethesia61,67,79. Similarly, insufficient data was reported to correlate complication with 
method of screening/guidance used or level of vertebra treated.  
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Table 2.2: Studies reporting serious complications (excluding deaths) 
 
Study No. 
Pt 
Serious  
Complications 
(%) 
Neuropathy 
requiring 
surgery 
Symptomatic 
PE/DVT 
Other 
Cotton 37 5.4% 2 0  
Weill 21 4.8% 1 0  
Martin 22 4.5% 0 1  
Mousavi 9 11.1% 1 0  
Chow 10 10% 1 0  
Barragan 117 1.7% 0 2  
Camels 52 11.5% 3 2 Haemathorax 
n=1 
Tseng 57 9.6% 3 0 Haematoma 
n= 2;  
1 requiring 
surgery 
Saliou 51 2.0% 1 0  
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Table 2.3 : Studies reporting mean cement volume and complications/deaths 
 
Author Mean 
Cement 
volume 
(ml) 
Complications 
(%) 
   Description of complications 
Yang 
 
5.1ml 0%  
Tseng 
 
5ml 12.2% 3 Neuropathy  (3 surgery, 2 died) 
2 Haematoma  (1 surgery) 
   
2 Deaths in hospital  
(1 respiratory failure,  
1 ischaemic heart disease) 
Barragan- 
Campos 
 
4.5ml 4.2% 2 Hyperalgia  
2 DVT/PE 
1 Death 
Calmels 
 
4.5ml 13.5% 3 Neuropathy (3 surgery)  
1 Hyperalgia  
2 DVT/PE 
1 Haemothorax 
Alvarez 
 
4.2ml 4.8%    1 Hyperalgia 
Kobayashi 
 
3.5ml 
(+/- 1.8ml) 
0%  
Trumm 
 
3.1ml 0%  
Anselmetti 
 
2.5ml 0%  
MtAlverne 
 
2.3ml 0%  
Barbero 
 
2.0ml 0%  
Pflugmacher 1.8ml 0%  
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Efficacy : Pain reduction 
 
Fifteen studies45,46,64,65,68-70,74-79,82,83, reported pain up to one month post-intervention with 
all showing a reduction in pain from baseline levels. Reduction in pain ranged from 20.3% 
to 78.9%. This effect appears to be sustained in eight studies46,68-70,75,78,79,82 (reduction in 
pain range from 46.9% to 86.6%) that went on to measure pain at six months (Table 2.4). 
One study reported increased pain in seven of 50 patients66.  
 
Studies that used a cement volume averaging less than 4mls reported a similar reduction in 
pain scores as those using larger volumes46,68,70,72,77(Table 2.5). 
 
Results on technical efficacy, function and quality of life were sporadically reported in the 
studies and were not significantly robust to be analyzed. 
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Table 2.4: Pain levels (VAS) Pre and Post vertebroplasty 
          
   Study     Pre-Intervention 1 month  6 months 
    
(no. of patients)  Baseline     
Alvarez  (21)    9.1  3.2  
Fourney (34)    8  2   2 
Mousavi (9)    9.5  3  
Diamond* (7)    7.6  1.6  
Kose* (16)    7.4  3          2.4 
Ramos (12)    7.5  3.7   1.9 
Pflugmacher (5)   6.3  2.4   1.5 
Anselmetti (12)   8.2  1.1 
Caudana (39)    8.6 (0.71) 2.8 (1.34)  
Masala (64)    8 (1.4)  1.8 (1.84)  1.9 (1.68) 
McDonald (67)   8.5 (0.35) 3.1 (1.25)  
Thang (27)    7.5  2.1  
Trumm (53)    6.4  5.1           3.4 
Tseng  (57)    8.1 (0.67) 3.8 (1.9)  2.6 (2.0) 
Chen (31)    8.9 (0.93) 2.6 (1.71)  3.12  
Kobayashi (33)   6.2 (2.1) 2.4 (2.3) 
Yang  (40)    8.78 (0.54) 5.4 (0.94) 
 
* VAS score standardised to 10 point scale, Data : Mean (SD). 
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Table 2.5 : Studies reporting cement volume and pain scores (VAS) 
Study Vertebra 
level 
No. Patients Pre-VP  
VAS 
Mean (SD) 
Post VP 
VAS 
Mean (SD) 
Complications 
Studies used <4ml cement volume : Myeloma only 
Pflugmacher C 5 6.3 2.4 None 
MtAlverne C 4 -  - None 
Metastases (including myeloma) 
Trumm C/T/L/S 53 6.4 5.1 None 
Kobayashi T/L 33 6.2 (2.1) 2.4 (2.3) None 
Anselmetti T/L 12 8.2 1.1 None 
Barbero NA 37 - - None 
Studies used >4ml cement volume: Metastases only 
Yang T/L 40 8.78 (0.54) 5.4 (0.94) None 
Tseng C/T/L 57 8.1 (0.67) 3.8 (1.9) 3 Neuropathy (3 
surgery, 2 died),  
2 Haematoma (1 
surgery),  
2 Deaths in 
hospital  
(1 respiratory 
failure,  
1 ischaemic heart 
disease) 
Camels C/T/L 52 - - 3 Neuropathy (3 
surgery),  
1 Hyperalgia, 2 
DVT/PE, 
1 Haemothorax 
Alvarez C/T/L 21 9.1 3.2 1 Hyperalgia 
Metastases (including myeloma) 
Barragan-Campos C/T/L 117 - - 2 Hyperalgia, 
2 DVT/PE 
1 Death 
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Discussion: 
 
This systematic review of vertebroplasty in patients with spinal metastases and myeloma 
revealed a paucity of robust data, and heterogeneity of available information (Table 2.1). 
While meta-analysis was not possible secondary to this, this review has showed that 
serious complications of vertebroplasty in this patient group ranged from 0% to 11.5%71. 
The mortality for the procedure ranged from 0% to 7%79. An average cement volume of 
4ml or greater may be associated with a higher complication rate than for those who had 
less than 4ml injected at vertebroplasty. While this finding appears to be clinically relevant, 
the data needs to be interpreted with caution, because it was based on a limited number of 
studies reporting on an average volume of cement injected. Correlation between the 
average amount of cement injected and overall complications has already been 
suggested10,59. It is thought that the overzealous quest for complete vertebral body filling 
results in increased complications59. 
 
The reduction in pain VAS found in this review of patients with spinal metastases is of a 
similar level to that reported for patients with osteoporosis82. Two recent randomised trials 
however have shown a reduced effect of vertebroplasty in osteoporosis - with a 2 and 3 
point reduction respectively in pain on a VAS54,55.  Moreover, both studies have indicated 
that in the short term at least, the benefit of placebo – that is local anaesthesia with sham 
procedure - is as good. This finding may be particularly relevant for patients with spinal 
metastases and limited life expectancy as a less invasive method of pain control. Research 
is required to assess this and if targeted local anaesthetic proves successful, this would 
have the added benefit of easy repetition if needed. 
 
Kyphoplasty has also been performed for patients with spinal metastasis and myeloma. 
There is no good evidence however that it is superior to vertebroplasty for either 
osteoporosis or tumour related vertebral compression fractures. In a review of 74 
vertebroplasty studies for osteoporosis, 35 kyphoplasty studies for osteoporosis and 18 
vertebroplasty and kyphoplasty studies for tumour, McGirt and colleagues was unable to 
show superiority of one procedure over the other86. In a recent systematic review on 
kyphoplasty in malignant spinal fractures by Bouza et al no serious procedure related 
complications were described87. In her study, 741 levels were treated in 306 patients. 
Asymptomatic cement leak occurred in 6% of all treated levels – which is lower than that 
reported previously82, 85,88.  
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It was not possible to perform a meta-analysis using the outcome data from the review. The 
included studies were heterogeneous with variations in patient types and the intervention 
performed. More specifically, the lack of a comparator group prevented a meta-analysis for 
the safety outcomes. In order to explore the effect of certain technical aspects of 
vertebroplasty (for example low vs high cement volume) on pain this would have required 
standard deviations to calculate a weighted mean difference. Standard deviations were 
reported in only 7 studies65,66,71,78,79,82,83. The limitations of this review relate to the quality 
of information available; data was collected prospectively in only 8 of the studies. The 
patients included had disparate underlying diagnoses and prognoses. While the primary 
end point was pain for most studies, only 17 reported pain using a visual analogue scale 
(VAS). Moreover, there was no standardization of when pain was measured, varying from 
one day to six months post procedure. While most studies recorded serious complications 
(mainly neuropathy), precise detail on outcome was often lacking. In particular 30 day 
mortality (the accepted standard for invasive surgical procedures) was not reported in most 
studies.  
 
Conclusion: 
 
This systematic review reveals the paucity of good quality, robust information available on 
the efficacy of percutaneous vertebroblasty in malignancy and highlights the invasive 
nature of vertebroplasty for patients with spinal metastasis or myeloma. Over 2% suffered 
a serious complication, which appeared to be related to the volume of bone cement injected 
at the time of vertebroplasty. As there is no evidence that larger volumes have a greater 
impact on pain reduction, this finding has important implications for the management of 
these patients. Further research is required to examine the benefit of targeted local 
anaesthetic as this may be suitable for patients who are undergoing concomitant systemic 
or local treatment for metastatic cancer.  
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Chapter 3 
 
A Prospective Study of Percutaneous 
Vertebroplasty in Patients with 
Myeloma and Spinal Metastases 
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Introduction: 
 
Since percutaneous vertebroplasty was first described by Galibert et al in 1987 for painful 
spinal haemangioma, the indication for and number of procedures performed have 
increased exponentially1. Percutaneous vertebroplasty is now an accepted treatment 
modality for osteoporotic, malignant and traumatic spinal fractures. In the United States, 
the number of procedure performed has doubled from 4.3 to 8.9 per 1000 Medicare 
enrollees in the last 6 years alone89 The attraction of vertebroplasty in malignant spine 
disease is its less invasive nature compared to open spinal surgery and the apparent rapid 
pain relief compared to radiotherapy and other conventional treatment options59,90,91.  
 
The incidence of bone metastasis is unclear. Up to 66% of patients with previous history of 
malignancy and back pain will have bone metastasis, yet up to 35% of patients with bone 
metastases are asymptomatic92,93. The prevalence of bone metastasis varies with different 
underlying malignancy – highest incidence seen in myeloma, prostate and breast cancer94. 
In addition, outcomes and median survival are significantly different for different 
diagnoses – for example median survival for patients with breast cancer and bone 
metastasis is 24 months versus 6 months for patients with lung cancer95. All these factors 
contribute to the difficulty in acquiring sufficient meaningful data on the role of 
vertebroplasty in malignancy. 
 
The literature on the role of vertebroplasty in spinal metastases consists mainly of 
retrospective studies and case reports assessing feasibility and safety. There are few 
prospective studies assessing pain and outcome. These studies have small patient numbers, 
method of assessment of outcome is variable and some suggest a high procedural related 
complication rate 10,11,67.   
 
The aim of this prospective study is to assess the outcome and complication rate of 
percutaneous vertebroplasty in a large cohort of consecutive patients with myeloma and 
spinal metastases treated over a 9 year period.  
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Patients and Methods: 
 
Percutaneous vertebroplasty has been performed by the senior author (RE) since 2001. 
Patient data have been collected prospectively since that time. This includes baseline 
demographics such as age, sex, underlying diagnosis, levels affected and treated, type of 
anaesthesia used as well as procedural related complications. Since 2005, pre- and post 
vertebroplasty pain questionaire and modified Roland-Morris Disability Questionaire have 
been collected by an independent research assistant. Patients are asked to document the 
worst pain during the day, which is measured on a visual analogue scale (VAS) between 0-
10, with 10 being the worst pain. The modified Roland-Morris Questionaire (RDQ) is 
scored on a scale of 0-23 with a higher score indicating a higher degree of disability. The 
RDQ is widely used to assess physical disability associated with back pain, and has been 
showed to be valid, reliable and responsive to change in several studies, including a recent 
randomised clinical trial into vertebroplasty in osteoporosis55. 
 
The technique of vertebroplasty used by the senior author has been described previously in 
detail55. Briefly, the vertebra to be treated is infiltrated with local anaesthetic under sterile 
conditions in the fluoroscopy suite. Opacified PMMA (less than 5ml) cement is injected 
under continuous fluoroscopic screening. Most procedures are performed under conscious 
sedation, with patients receiving intravenous sedation and analgesia, usually midazolam 
and fentanyl. Patients are kept on strict bed rest for 2 hours and allowed home either the 
same or the following day. Patients are reviewed at 1 month at clinic, and receive repeat 
questionnaires at 6 weeks post procedure.  
 
The indications for vertebroplasty in malignancy include intractable pain from metastases 
and vertebral collapse unresponsive to oral analgesia, as well as an adjunct to planned 
radiotherapy. Uncontrolled coagulopathy, infection, spinal cord compression and complete 
vertebral collapse are contra-indications. No more than 4 vertebrae were injected at a 
single procedure, and the volume of cement volume was kept to less than 5ml per injected 
vertebra. 
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Statistics: 
VAS and RDQ scores were expressed as mean with standard deviation. Comparison 
between groups was made using the Mann-Whitney-U, 2 tailed test. Duration of survival 
was expressed as a median with range. The estimated survival was calculated using the 
Kaplan-Meier method. Comparison between groups was made using the Log Rank 
(Mantel-Cox) test. All statistical analyses were performed using the SPSS version 18.0 
software. 
 
 
 
Results: 
One hundred and twenty eight patients (60 female, 68 male) underwent 158 percutaneous 
vertebroplasty procedures for malignant spine disease between June 2001- June 2010. The 
mean age was 60 years (range 31-88 years). Forty-one patients had multiple myeloma 
while 87 had spinal metastases. The most common primary malignancies and patient 
demographics are shown in Table 1. Other primaries included oesophagus, colorectal and 
tongue etc. Twenty four patients underwent multiple treatments. Two hundred and sixty-
four thoracic and lumbar vertebrae were treated during this period. Four procedures were 
unsuccessful, because the lesions were too sclerotic in two patients and two others were 
unable to tolerate conscious sedation. The procedures were repeated under general 
anaesthesia for the latter. 
 
Fifty patients returned completed pain scores pre- and 6 weeks post vertebroplasty. On an 
intention to treat basis, the mean VAS score fell from 7.57 (+/- 1.88) pre-vertebroplasty to 
4.77 (+/- 2.67) post-vertebroplasty (p < 0.001) (Table 2). Nine (18%) patients had no 
reduction or a slight increase in pain scores. Thirty-eight patients completed pre- and 6 
weeks post-procedural Roland-Morris questionnaires. On an intention to treat basis their 
scores fell from a mean of 18.55 (+/- 4.79) to 13.5 (+/-6.95) (p < 0.001). Nine (24%) had 
no improvement in disability scores, however only 3 of those did not have a reduction in 
pain scores. 
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Table 3.1: Patient demographics 
 
 
Total no. patients  
Male 
Female 
      128 
       68 
       60 
Mean age  
(range) 
      60 years 
    (31-88) 
Underlying diagnoses : 
 
Myeloma 
 
 
        41 
Metastasis 
a. Breast    
b. Lung 
c. Lymphoma 
d. Renal 
e. Prostate   
f. Others                         
        87 
        22 
        16 
        11 
         8 
         5 
        25 
Total no. of vertebrae treated        264 
 
          
Total number of procedures        158 
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Table 3.2: Pain and Disability scores pre and post-vertebroplasty 
 
 Pre 
Vertebroplasty 
Post 
vertebroplasty 
(6 weeks) 
         p value 
*VAS      7.57 +/- 1.88     4.77 +/- 2.67            0.001 
* RDQ   18.55 +/- 4.79    13.5  +/- 6.96            0.001 
 
 
* Values are mean +/- standard deviation. p values calculated using Mann-Whitney U, 2 
tailed test. 
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Complications: 
 
Asymptomatic small para-vertebral leaks were sometimes observed and were not 
considered further in this study. Complications were recorded in three patients, cement 
extension into the inferior vena cava (1), local haematoma (1) and loss of sensation at T1 
dermatome (1). The patient with IVC cement extension had an IVC filter placed 
prophylactically. There were three observed asymptomatic pulmonary emboli of which one 
patient underwent groin cut down and extraction of cement because the size of embolus 
was deemed too large.  
 
Seven (5%) patients died within 30 days of vertebroplasty (2 prostate cancer, 2 multiple 
myeloma, 1 bladder, 1 renal and 1 lung cancer). The causes of death were: 
bronchopneumonia (2), renal failure (2), left ventricular dysfunction (1), intracranial 
haemorrhage after a fall (1) and myeloma disease progression (1). Three patients had 
symptoms of opioid toxicity post-procedure, despite reporting good pain relief. In one 
patient this led to several falls and secondary intracranial haemorrhage. 
 
Long term follow up 
Long term follow up was achieved in 39 of 41 patients with multiple myeloma and in 79 of 
87 patients with spinal metastases from other cancers. The median survival for myeloma 
patients was 20 months (rang 2-29 months), while survival for those with metastases was 8 
months (range 1 week – 107 months). The Kaplan-Meier estimate of 5 year survival from 
the date of vertebroplasty in the myeloma group was 40%. This compared to an estimated 
5 year survival of 25% for bone metastases (Fig 1). There were eight patients in this group 
surviving longer than 4 years, with metastases from breast cancer (4), seminoma (2), renal 
cancer (1) and lymphoma (1) – Table 3.3. 
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Figure 3.1: Survival curve for patients with myeloma and metastases 
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Table 3.3 : Kaplan – Meier Survival estimates for Myeloma and Metastases 
 
 
Myeloma: 
6mth  1y  2y  3y  4y  5y 
No. at risk     
38/39  30/33  18/24  13/14  8/10  4/6 
 
KM estimate     
0.97  0.88  0.66  0.62  0.49    0.33 
 
Metastases : 
 
No. at risk     
47/79  28/38  18/25  12/14  8/9  7/7 
KM estimate    
0.59  0.44  0.32  0.27  0.24    0.24 
 
At 4 years -  8 long term survivals: 
4 breast 2 seminoma 1 renal 1 lymphoma 
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Discussion: 
 
This study shows that most patients with pain from spinal metastases receive rapid relieve 
from percutaneous vertebroplasty. Disability is also significantly improved and serious 
complications are rare. 5% of patients died within 30 days of the procedure, the causes of 
death would appear to be related to the late referral of patients with either advanced disease 
or opioid toxicity. No patient died from a procedural related complication. The estimated 5 
year survival of patients with spinal metastases from breast and other cancers was 25%. 
This compared to 40% for myeloma patients, and highlights the important role of 
percutaneous vertebroplasty in the ever improving multimodality treatment of these 
patients. 
 
Our results compares favourably with the studies available in the literature9. Overall, the 
pain scores fell by 2.8 point on the VAS, which is statistically significant, and in line with 
the improvement observed in two recent randomised clinical trials into vertebroplasty for 
osteoporosis8,10. These trials reported a complication rate of 1.5%, none of which were 
serious. In contrast, a serious complication rate of approximately 2% has been observed 
with percutaneous vertebroplasty for malignant disease96. The reason for this is unclear, but 
may be related to the use of higher cement volumes for metastases. A cement volume of 
less than 5ml was injected in this study, and while cement clearly entered the venous 
system, all patients were asymptomatic. In addition, no patient developed a major 
neurologic deficit as a result of spinal cord or nerve root compression. 
 
Treatment for spinal metastasis is palliative – with a view of controlling pain, stabilising 
the spine and reducing the effects of hypercalcaemia. The cause of bone/back pain from 
metastasis is poorly understood. Mechanical instability and neurogenic pain from 
periosteal irritation have been proposed as possible causes95. Although pain scores were 
collected at 6 weeks post-vertebroplasty in our study, patients reported an analgesic effect 
almost immediately. Several theories have been put forward as to how the analgesic effect 
is achieved – local anaesthesia effect, mechanical stabilisation, thermal effect of the 
cement on tumor cells/nerve endings – but none have been conclusive59. Interestingly, the 
randomised trials of vertebroplasty in osteoporosis reported similar improvement in pain 
scores between vertebroplasty and the sham procedure54,55. The role of periosteal 
infiltration with local anaesthesia alone therefore merits further investigation, particularly 
in patients with spinal metastases and a limited life expectancy. This may also help in 
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assessing patients likely to respond to vertebroplasty as nearly 20% of patients in our study 
had no reduction on the VAS.  
 
Localised bone pain is treated routinely with radiotherapy. Around 55% of patients achieve 
partial or complete pain relief with this modality at one month. The median onset of pain 
relief is greater than 4 weeks for half the patients that respond and the median duration of 
pain relief is just 12 weeks97. As a result, percutaneous vertebroplasty has gained 
popularity as a pre-radiotherapy adjunct in the treatment of bone metastasis as it is 
minimally invasive, safe, appears to produce almost immediate analgesic effect and 
potentially stabilises the vertebral body by preventing further collapse. Moreover, pain 
relief appears more durable with vertebroplasty, showing sustained pain relief for 6 months 
or longer11,55. 
 
Conclusion: 
This is the largest prospective study looking into the efficacy and complications of 
vertebroplasty in malignant spine disease. The reduction in pain score and improvement in 
disability for most patients is highly significant with this minimally invasive procedure and 
has a low rate of serious complications. Percutaneous vertebroplasty now forms an 
important part of the multi-modality treatment for patients with intractable pain from 
myeloma and bone metastases. 
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Chapter 4 
 
Health Service Cost associated with 
Percutaneous Vertebroplasty in 
patients with Spinal Metastases  
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Introduction: 
 
Vertebroplasty was first described by Galibert in 1987 as a treatment for painful vertebral 
angioma1. Since then, its use has expanded to include treatment for osteoporotic wedge 
fractures, spinal metastases and spinal trauma. In 2007, a multisociety consensus statement 
concluded that vertebroplasty was a safe and efficacious treatment for osteoporosis98. A 
recent open label randomised trial concluded that vertebroplasty for acute osteoporotic 
fractures had an acceptable cost of €22,685 per quality-adjusted life year (QALY) gained 
when compared to conservative management57. Little information is available regarding 
the cost of vertebroplasty in the setting of malignancy – in a group of patients who may 
have a limited life expectancy and severe intractable pain.  
 
NICE approved the use of vertebroplasty or kyphoplasty for patients with spinal metastases 
in November 200847.  This was based on expert opinion with costing calculated on the 
procedure performed under general anaesthetic and protracted inpatient stay. 
 
The aim of this study was to ascertain prospectively the health service cost of 
vertebroplasty on a cohort of consecutive patients with spinal metastases. 
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Patients and Materials: 
 
Vertebroplasty for spinal metastases has been performed at our institution by the senior 
author since 2001. The procedure is performed under conscious sedation and local 
anaesthetic in the Interventional Suite with fluoroscopic guidance. Data was collected 
prospectively on standard forms in a consecutive series of patients undergoing 
vertebroplasty for spinal metastases between August to December 2011. Quality of life 
questionnaires (EQ-5D) were filled out pre-, six weeks and at six months post-
vertebroplasty. 
 
Measurement of costs: 
 
Operative costs 
 
Theatre running costs was based on the Department of Health published national schedule 
of reference cost99. This was combined with variable operative costs. To obtain the most 
accurate data, operative costs relating to percutaneous vertebroplasty (equipment and 
consumables) were identified and measured prospectively. A structured questionnaire was 
completed during a sample of operations. For items of equipments, an estimation of their 
lifespan was obtained, as well as any maintenance cost and approximation of the number 
of times used. From this, an annual equivalent cost is estimated and divided by the annual 
use to obtain a cost per hour per patient.  The staffing element of the theatre costs was 
based on the team – reflecting the grade of radiologist and assistant, as well as the number 
and grade of radiographic and nursing staff. Where complications were identified, cost of 
each event would have been compiled and attached as a “complication cost”.  
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Other healthcare costs 
 
The cost of an inpatient day (including staffing, capital charges and overheads) on a 
general medical ward was also based on the Department of Health figures99. For each 
patient, this cost was multiplied by the total inpatient stay. Drugs were costed according to 
the manufacturers’ price list 
 
The cost of imaging pre-vertebroplasty was not included in this exercise as they were 
performed as part of the patients’ routine follow up. 
 
Mean cost for percutaneous vertebroplasty was calculated using individual patient data 
refined with the additional more detailed information from the procedure cost 
questionnaire. The cost data was analysed by intention to treat.  
 
Health Status: 
 
The EQ-5Q questionnaire was used for the economic evaluation to permit the calculation 
of QALYs. Data was collected pre- and 6 weeks post-vertebroplasty for 10 patients. Data 
was also collected after at least 6 months to assess long term change, if any. The EQ-5D is 
a generic measure of health status that defines health in terms of five broad dimensions, 
each with three levels (Table 4.1).Combinations of these dimensions and levels gives rise 
to 243 health states. These health states were given QOL scores by a sample of the general 
public and a UK tariff compiled100,101. 
 
 
 
 
Statistical analysis: 
Data is expressed as median with range. Summary statistics of the baseline utility score are 
given as mean values with standard error. The level of significance was set at 0.05. Data 
was processed using Microsoft® Office Excel 2003. 
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Table 4.1: The EQ-5D descriptive system 
Mobility 
1  No problems in walking about 
2  Some problems in walking about 
3  Confined to bed 
Self care 
1  No problems with self care 
2  Some problems with washing or dressing myself 
3  Unable to wash or dress myself 
Usual activities 
1 No problems with performing usual activities (eg work, study, housework,  
family or leisure activities) 
1 Some problems with performing usual activities 
2 Unable to performed usual activities 
 
Pain/Discomfort 
1 No pain or discomfort 
2 Moderate pain or discomfort 
3 Extreme pain or discomfort 
 
Anxiety/Depression 
1 Not anxious or depressed 
2 Moderately anxious or depressed 
3 Extremely anxious or depressed 
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Results: 
 
Of the eleven consecutive patients who underwent vertebroplasty over the four period, 
eight were performed as planned outpatient procedures and three were referred with 
intractable pain whilst in hospital. Two planned outpatient procedures were performed as 
day cases. Five required overnight stay in a general ward because of social circumstance or 
distance from home, while one stayed in hospital for two days as his procedure was 
cancelled and rescheduled. Two of the inpatients were able to be discharged from hospital 
one and two day post-vertebroplasty, while the third patient died two weeks post 
vertebroplasty from his primary malignancy.   
 
Most of the patients underwent vertebroplasty for one (n=5) or two (n=5) levels. One 
patient had three spinal levels treated. The median time of the procedure was 60 minutes 
(range 40-80 minutes) with a median time of 60 minutes (range 10-230 minutes) spent in 
recovery pre- and post- procedure.  All procedures were performed with conscious sedation 
and local anaesthetic in the radiology intervention suite.  Staffing involved one Consultant 
radiologist, four nurses (two in recovery, two in the intervention suite) and two 
radiographers. A senior radiology registrar was involved in five of the cases. 
 
Health Service costs: 
 
Personnel and equipment costs are illustrated on Tables 4.2 and 4.3. Based on these 
figures, the average cost of vertebroplasty per patient – including consumables, capital 
equipment, hotel/clinic costs and staffing – is £2213.25 (range £1,581.72- £6,076.72, 95% 
C.I £729.95). 
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Table 4.2: Staff costs per hour* 
Consultant Radiologist  (n=1)                  £67.30 
Registrar (n=1 – in 5 cases)                  £18.30 
Radiographers (n=2)                  £30.80 
Nurses (n=4)                  £61.50 
*Based on published salaries:  consultant, registrar (5th year), nurse (Band 6), radiographer 
(Band 6).  
Table 4.3: Hotel and Equipment costs% 
Pre-vertebroplasty clinic appointment  
Post vertebroplasty clinic appointment  
               £161 
               £157 
Overnight hospital stay                £371 
Day case hospital stay                £171 
Interventional Fluoroscopy Unit (cost per hour)                45.20 
Consumables and Drugs (per patient)  
-  Vertebroplasty kit                 £744.00 
-  Theatre pack, gloves, gowns, needles, syringes                 £139.46 
-  Lignocaine, Midazolam, Cefuroxime, Fentanyl                 £4.51  
 %Based on  Department of Health published  national schedule of reference cost. 
 #Based on a 10 year machine life span, capital cost £500,000 maintenance cost 
£44,000 per annum. 
  
72 
 
Mean EQ-5D utility scores increased from 0.4392 pre-treatment to 0.5398 post-treatment 
(p=0.225, 2 tailed paired student t-test). Four patients did not improve their utility scores. 
In two, pain was secondary to concomitant benign bone disease rather than metastasis: a 
subsequent insufficiency pubic fracture from previous radiotherapy in one and 
degenerative change at the facet joint in the other. When these two patients were excluded, 
the utility scores increased from 0.421 pre-treatment to 0.5979 post-treatment (p=0.047). 
 
The visual analogue scale (VAS) of perceived health improved from a mean of 46.5 to 59.5 
(p=0.156). This effect was sustained at 6 months (n=8, mean VAS 66.7). When the two 
patients with benign disease were excluded, the mean VAS rose from 41.88 to 63.75 
(p=0.00537).  
 
Based on a consecutive series of 128 patients undergoing vertebroplasty for spinal 
metastasis in our unit, the median survival for patients with myeloma was 20 months 
(range 2-91 months) while that for patients with metastases was 8 months (range 1 week to 
107 months)8. The cost per QALY was calculated at £23,545.21 for patients with myeloma 
and £58,706.90 for patients with metastatic disease.   
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DISCUSSION 
 
The average cost of percutaneous vertebroplasty in this study is £2,213.25 (range £1581.72 
– £6076.72). This figure is increased substantially by the patient who presented acutely 
with widespread metastatic bronchial carcinoma and died in hospital 13 days post-
vertebroplasty.  If the procedure were to be performed as a day case or with overnight stay 
– as in the majority of our patients – then the average cost becomes £1,740.87. These 
figures are comparable to the cost of deploying a palliative oesophageal or colonic 
stent102,103. 
 
National Institute for Health and Clinical Excellence (NICE) 2008 recommendations 
regarding the role of vertebroplasty in the setting of spinal metastases placed the cost at 
£9,35053. The difference in cost between our studies is related to multiple factors 
including : - the procedures were performed under general anaesthesia with a longer 
procedure time (2.72 hours), associated theatre personnel costs, implant cost (£2,696) and 
length of stay in high dependency unit (one day, £900) and acute medical ward (nine days, 
£2184). Even though the cost was much higher, vertebroplasty was still considered cost-
effective for ambulating patients. This is based on the premise of early treatment 
improving pain control, quality of life and preventing malignant cord compression in 
patients deemed likely to survive more than three months. 
 
In our experience, most patients tolerate the procedure well under conscious sedation and 
local anaesthesia. Inpatient stay was often only necessary because of the patient’s social 
circumstance or distance between home and hospital. A significant proportion of our 
patients are referred while an inpatient receiving treatment for intractably bone pain and 
are successfully discharged days after vertebroplasty. None of our patients required high 
dependency care. No patients underwent vertebroplasty when spinal cord compression was 
imminent. Our experience previously published demonstrates a similar reduction in pain 
and improvement in disability in patients with underlying bone metastases when compared 
to those in recently published trials for osteoporosis54,55. 
 
Cost effectiveness or cost per QALY is linked to overall survival. Median survival for 
patients with bone metastases ranges from 2-3 months in upper Gastrointestinal and 
bronchial carcinoma to 1-2 years in breast cancer and lymphoma. This is reflected in our 
study where the cost of vertebroplasty per QALY for patients with metastasis is £58,706.90 
74 
 
(median survival 8 months) compared to £23,545.21 for patients with myeloma (median 
survival 20 months). This perhaps should be borne in mind when considering patient 
suitability for vertebroplasty where other forms of pain relief maybe considered in those 
with very short life span. Currently the only recognised tool enabling clinicians to estimate 
survival is the Eastern Cooperative Oncology Group performance status where patients 
with performance status grade 4 are likely to have survival measurably in weeks. As 
patients with spinal metastases are often confined to bed or chair (ECOG performance 
status grade 4) this however may not be a reliable tool for assessing this group of patients.   
 
This is the first study to attempt an accurate quantification of the cost to the Health Service 
of percutaneous vertebroplasty in patients with spinal metastases. Although the sample size 
used to estimate cost was small, it is part of a much larger consecutive series of patients 
undergoing vertebroplasty with long term follow up96. 
 
 
 
CONCLUSION  
 
Health service cost for percutaneous vertebroplasty in patients with spinal metastases is 
significantly lower than previously estimated and is in keeping with that of other palliative 
radiological procedures. 
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Chapter 5 
 
Summary 
And 
Discussion  
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SUMMARY AND DISCUSSION 
 
The literature on the subject of percutaneous vertebroplasty in spinal metastasis is 
composed of generally poor quality information. Only 30 studies with sufficient 
information were included in our systematic review. Of these, there was 1 randomised 
controlled trial, 7 prospective and 20 retrospective studies – the remaining two studies had 
unclear methodology. No good quality information has been published since. 
 
The documented efficacy in pain relief ranged between 20 – 79% reduction in the pain 
scores. Only 8 studies had long term (6 months) follow up and the effect on pain relief 
appears sustained. In one study, 14% of patients reported increased pain post 
vertebroplasty. The effect on pain relief appears unrelated to the volume of cement used. 
 
The rate of serious complications is over 2% - including death, neuropathy requiring 
emergency surgical decompression, haematoma, haemthorax, deep venous thrombosis and 
symptomatic cement pulmonary embolus. There was a trend towards increased 
complications when larger cement volumes were used. Vertebroplasty attributable deaths 
were reported in centres using general anaesthesia preferentially over local anaesthesia. 
 
Our study is the largest published prospective series of percutaneous vertebroplasty in 
spinal metastasis with long term follow up. The reduction in pain VAS and improvement in 
disability (Roland-Morris score) were highly significant. Although this reduction in VAS (-
2.8) is less than those reported previously, it is in line with the results reported by the 
randomized controlled trials in osteoporosis. Up to 18% of our patients did not report any 
improvement in their pain.  
 
We had no serious complication in our series, with only a 1.5% incidence of minor or 
asymptomatic cement leaks. The 30 day mortality was 5% - all with advanced disease and 
thought related to the late referral of these patients. 
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There is clearly great variability in the outcomes and results achieved in different centres 
by different practitioners. While this may in part be related to the methodology of 
reporting, it does raise the important issue of who should be performing this procedure. 
Vertebroplasty is currently performed by spinal and orthopaedic surgeons, 
neuroradiologists and interventional radiologists and even anaesthesiology interventional 
pain specialists. Further issue regarding adequate training and supervision of these 
practitioners is also raised. Is there a minimum number one should be performing under 
supervision/proctorship before being allowed independent practice? Should there be a 
minimum number of procedures performed per annum? Should practitioners be 
accreditated and results audited as is happening for many other interventional or invasive 
procedures eg endoscopy completion rate, outcome following colorectal surgery for cancer 
etc? 
 
More recently published data relates mainly to percutaneous vertebroplasty in 
osteoporosis. These include the VERTOS II trial (2010) which compared vertebroplasty 
with best medical management in acute osteoporotic fractures and a sub study of INVEST 
– the LABEL study (2010) which looked at the efficacy of local anaesthetic alone in 
osteoporotic fractures57,104. VERTOS concluded that pain relief after vertebroplasty is 
immediate, is sustained for at least a year, and is significantly greater than that achieved 
with conservative treatment, at an acceptable cost. LABEL concluded that despite 
improvement in dynamic pain and function at 24 and 72 hours, an unblended injection of 
local anaesthesia is ineffective in treating pain from osteoporotic compression fracture. 
This suggests factors other than local anaesthesia were responsible for the observed 
improvement in the vertebroplasty group in INVEST. The VERTOS IV trial, comparing 
vertebroplasty with sham procedure in acute vertebroplasty, is still recruiting (personal 
communication). The Italian EVEREST study looked at vertebroplasty for all unselected 
indications and concluded that the best results were achieved with treatment for myeloma 
and trauma105. 
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The CAFÉ Medtronic funded study (2011) looked at balloon kyphoplasty versus non-
surgical management for treatment of painful vertebral fractures in patients with cancer106. 
This demonstrated a highly significant improvement in the Roland-Morris score at 1 
month, but no significant improvement to the pain scores. They also reported a serious 
adverse event rate of 37% within one month and 52% after one month post kyphoplasty. 
This included a myocardial infarction and intermittent atrial fibrillation attributed to the 
anaesthesia, a device related serious adjacent vertebral fracture, a wound infection and 
balloon rupture.  
 
Interestingly, another Medtronic funded large study comparing balloon kyphoplasty and 
vertebroplasty in osteoporosis (NCT00323609) was terminated prematurely with no 
information regarding the reason nor any results published subsequently.   
 
Recently published NICE guidelines for percutaneous vertebroplasty and balloon 
kyphoplasty for treating osteoporotic vertebral compression fracture concluded that based 
on the information available – including two (Medtronic funded) observational studies 
showing mortality benefit of vertebroplasty/kyphoplasty over conservative management – 
intervention is cost effective and recommended as options in patients with severe ongoing 
pain after a recent unhealed vertebral fracture despite optimal pain management107. 
 
We calculated the cost of percutaneous vertebroplasty in spinal metastasis at £2213.25. 
This was much lower than the costing (£9,350) used by NICE in their economic analysis 
which still concluded that vertebroplasty was cost effective when compared to no treatment 
in the setting of ambulant patients with spinal metastasis. The information provided to 
NICE is in the form of “expert opinion” and costs were escalated by the use of general 
anaesthesia, long hospital stays in high dependency units and inpatient wards as well as 
slightly more expensive vertebroplasty kits.  
 
Cost effectiveness is related to survival post procedure – the calculated QALY for 
myeloma (median survival of 20 months) is £23,545 when compared to £58,706 for spinal 
metastasis (median survival 8 months). This is in line with costs quoted for other palliative 
radiological procedures such as the deployment of oesophageal and colonic stents. 
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Given the above, it would seem reasonable to suggest patients with painful spinal 
metastases – particularly from myeloma – should be referred earlier in their disease to 
maximize the potential benefit.  
 
There has been suggestions that patients with painful spinal metastasis may benefit as 
much from bedside injection of only local anaesthesia – no cement/vertebroplasty - to the 
affected vertebra – based on the Buchbinder/INVEST trial demonstrating no benefit in 
vertebroplasty over sham procedure in osteoporosis. Anecdotal evidence, including local 
experience, suggests immediate pain relief. One patient with metastatic breast cancer was 
able to walk down the aisle to get married a few days after one injection of local 
anaesthetic. Although the effect may not be long lasting, injecting local anaesthesia is a 
relatively straightforward bed side procedure and easily administered repetitively, while at 
the same time avoiding the complications associated with trocar insertion and cement 
injection into bone.  
 
Critics however cite the LABEL study suggesting no benefit of local anaesthetic alone in 
osteoporotic fractures. They also highlight the apparent cancerocidal effect of PMMA up to 
6 months post-injectionx as well as the potential thermal induced destruction of periosteal 
nerves endings which could contribute to the overall efficacy of vertebroplasty.  
 
Local anaesthetic periosteal infiltration should be considered and may be better suited to 
terminally ill patients with limited life expectancy who may not tolerate vertebroplasty but 
would still benefit from local palliative pain relief for bone pain. A new scoring system 
with 99.8% specificity and 96% positive predictive value for identifying patients unlikely 
to survive 2 months could be very helpful in identifying these patients108. 
 
Is there a need for a large prospective randomized controlled study examining the role of 
percutaneous vertebroplasty in spinal metastasis? Probably not. While no robust, well 
designed large randomized trial is available in this specific area – which is composed of a 
heterogeneous cohort of particularly vulnerable and difficult to treat patients - existing 
information appears to point towards reasonable safety, efficacy and cost effectiveness. It is 
now part of the repertoire of options available to clinicians to treat painful spinal 
metastasis. 
80 
 
It is evident that early diagnosis and referral for vertebroplasty is key in treating painful 
spinal metastasis. Patients with opioid toxicity or in the terminal stages of their disease are 
less likely to have maximum benefit from this minimally invasive but nonetheless complex 
procedure with not insignificant potential complications. It is important therefore to 
educate clinical oncologists and palliative care specialists the role of vertebroplasty in 
spinal metastasis and to encourage early referral for this group of patients. 
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Appendix 1: 
 
Brief Pain Index (Short form) 
Roland – Morris Disability Score 
EuroQol EQ-5D  
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STUDY ID#           HOSPITAL #    
DO NOT WRITE ABOVE THIS LINE 
Brief Pain Inventory (Short Form) 
 
 
 
Date:   /   /      Time:   
 Name:            
Last           First                 Middlle Initial 
1. Throughout our lives, most of us have had pain from time to time (such as minor 
headaches, sprains, and toothaches).  Have you had pain other than these every- 
day kinds of pain today? 
 
1.    Yes 2.     No 
 
2. On the diagram, shade in the areas where you feel pain.  Put an X on the area that 
hurts the most. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Please rate your pain by circling the one number that best describes your pain at its 
worst in the last 24 hours. 
0 1 2 3 4 5 6 7 8 9 10 
No Pain as bad as 
Pain you can imagine 
 
4. Please rate your pain by circling the one nuimber that best describes your pain at its 
least in the last 24 hours. 
0 1 2 3 4 5 6 7 8 9 10 
No Pain as bad as 
Pain you can imagine 
 
5. Please rate your pain by circling the one number that best describes your pain on 
the average. 
0 1 2 3 4 5 6 7 8 9 10 
No Pain as bad as 
Pain you can imagine 
 
6. Please rate your pain by circling the one number that tells how much pain you have 
right now. 
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The Roland-Morris Disability Questionnaire 
 
When your back hurts, you may find it difficult to do some of the things you normally do. 
 
This list contains sentences that people have used to describe themselves when they have back pain.  
When you read them, you may find that some stand out because they describe you today.   
 
As you read the list, think of yourself today.  When you read a sentence that describes you today, put a tick 
against it.  If the sentence does not describe you, then leave the space blank and go on to the next one.  
Remember, only tick the sentence if you are sure it describes you today. 
 
1. I stay at home most of the time because of my back.  I change position frequently to try and get my back 
comfortable.   
2. I walk more slowly than usual because of my back. 
3. Because of my back I am not doing any of the jobs that I usually do around the house. 
4. Because of my back, I use a handrail to get upstairs. 
5. Because of my back, I lie down to rest more often. 
6. Because of my back, I have to hold on to something to get out of an easy chair. 
7. Because of my back, I try to get other people to do things for me. 
8. I get dressed more slowly then usual because of my back. 
9. I only stand for short periods of time because of my back. 
10. Because of my back, I try not to bend or kneel down. 
11. I find it difficult to get out of a chair because of my back. 
12. My back is painful almost all the time. 
13. I find it difficult to turn over in bed because of my back. 
14. My appetite is not very good because of my back pain. 
15. I have trouble putting on my socks (or stockings) because of the pain in my back. 
16. I only walk short distances because of my back. 
17. I sleep less well because of my back. 
18. Because of my back pain, I get dressed with help from someone else. 
19. I sit down for most of the day because of my back. 
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20. I avoid heavy jobs around the house because of my back. 
21. Because of my back pain, I am more irritable and bad tempered with people than usual. 
22. Because of my back, I go upstairs more slowly than usual. 
23. I stay in bed most of the time because of my back. 
 
Note to users: 
 
This questionnaire is taken from: Roland MO, Morris RW. A study of the natural history of back pain.  Part 
1: Development of a reliable and sensitive measure of disability in low back pain. Spine 1983; 8: 141-144  
 
The score of the RDQ is the total number of items checked – i.e. from a minimum of 0 to a maximum of 24. 
 
It is acceptable to add boxes to indicate where patients should tick each item. 
 
The questionnaire may be adapted for use on-line or by telephone. 
 
 
 
 
 © 1990 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group 
 
EUROQOL 
 
 
 
 
Health Questionnaire 
 
English version for the UK 
(validated for Ireland) 
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© 1990 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group 
 
By placing a tick in one box in each group below, please indicate which statements 
best describe your own health state today. 
 
Mobility 
I have no problems in walking about        
I have some problems in walking about       
I am confined to bed          
 
Self-Care 
I have no problems with self-care        
I have some problems washing or dressing myself      
I am unable to wash or dress myself        
 
Usual Activities (e.g. work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities     
I have some problems with performing my usual activities     
I am unable to perform my usual activities       
 
Pain/Discomfort 
I have no pain or discomfort         
I have moderate pain or discomfort        
I have extreme pain or discomfort        
Anxiety/Depression 
I am not anxious or depressed       
I am moderately anxious or depressed       
I am extremely anxious or depressed        
 
To help people say how good or bad a health state is, we have 
drawn a scale (rather like a thermometer) on which the best state you can 
imagine is marked 100 and the worst state you can imagine is marked 0. 
 
We would like you to indicate on this scale how good or bad your own 
health is today, in your opinion. Please do this by drawing a line from 
the box below to whichever point on the scale indicates how good or 
bad your health state is today. 
 
 
 
 
 
 
Your own 
Your own 
 
 
 
Your own  
health state  
today 
9 0 
8 0 
7 0 
6 0 
5 0 
4 0 
3 0 
2 0 
1 0 
100 
Worst  
Imaginable 
 health state 
0 
Best  
imaginable  
health state 
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Appendix 2: Systematic review Search Strategy 
Medline (OBS) Search Strategy  
1. Epidemiologic studies/ 
2. exp case control studies/ 
3. exp cohort studies/ 
4. case control.tw. 
5. (cohort adj (study or studies)).tw. 
6. cohort analy*.tw. 
7. (follow up adj (study or studies)).tw. 
8. (observational adj (study or studies)).tw. 
9. longitudinal.tw. 
10. retrospective.tw. 
11. cross sectional.tw. 
12. cross-sectional studies/ 
13. or/1-12 
14. exp Vertebroplasty/ 
15. (kyphoplasty or cementoplasty or vertebroplasty or sacroplasty).tw. 
16. exp Bone Cements/ 
17. bone cement*.tw. 
18. 14 or 15 or 16 or 17 
19. exp neoplasms/ 
20. (cancer* or carcin* or neoplas* or oncolog* or malignan*or metast* or tumour* or tumor*or 
myeloma*).tw. 
21. Spinal Fractures/ 
22. Spinal Neoplasms/ 
23. Fractures, compression/ 
24. compression fracture*.tw. 
25. (spine or spinal).mp. and (fracture* or neoplas* or cancer* or carcin* or oncolog* or malignan* or 
metast* or tumour* or tumor* or *myeloma*/).tw. 
26. osteoporosis/ 
27. osteoporotic.tw. 
28. 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 
29. 28 and 18 and 13 
30. limit 29 to (english language and humans) 
 
Medline (RCT) Search Strategy  
1. Randomized Controlled Trials/ 
2. randomized controlled trial.pt. 
3. Random Allocation/ 
4. Double-Blind Method/ 
5. Single-Blind Method/ 
6. Clinical trial.pt. 
7. exp clinical trials/ 
8. or/1-7 
9. (clinic$ adj trial$1).tw. 
10. ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3)).tw. 
11. Placebos/ 
12. Placebo$.tw. 
13. Randomly allocated.tw. 
14. (allocated adj2 random).tw. 
15. or/9-14 
16. 8 or 15 
17. Case report.tw. 
18. Letter.pt. 
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19. Historical article.pt. 
20. Review of reported cases.pt. 
21. Review, multicase.pt. 
22. or/17-21 
23. 16 not 22 
24. exp Vertebroplasty/ 
25. (kyphoplasty or cementoplasty or vertebroplasty or sacroplasty).tw. 
26. exp Bone Cements/ 
27. bone cement*.tw. 
28. 24 or 25 or 26 or 27 
29. exp neoplasms/ 
30. (cancer* or carcin* or neoplas* or oncolog* or malignan*or metast* or tumour* or tumor*or 
myeloma*).tw. 
31. Spinal Fractures/ 
32. Spinal Neoplasms/ 
33. Fractures, compression/ 
34. compression fracture*.tw. 
35. ((spine or spinal) and (fracture* or neoplas* or cancer* or carcin* or oncolog* or malignan* or 
metast* or tumour* or tumor*or myeloma*)).tw. 
36. osteoporosis/ 
37. osteoporotic.tw. 
38. 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 
39. 28 and 38 and 23 
40. limit 39 to humans 
41. limit 40 to english language 
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Embase (OBS) Search Strategy  
 
1. Clinical study/ 
2. Case control study/ 
3. Family study/ 
4. Longitudinal study/ 
5. Retrospective study/ 
6. Prospective study/ 
7. Randomized controlled trials/ 
8. 6 not 7 
9. Cohort analysis/ 
10. (Cohort adj (study or studies)).mp. 
11. (Case control adj (study or studies)).tw. 
12. (follow up adj (study or studies)).tw. 
13. (observational adj (study or studies)).tw. 
14. (epidemiologic$ adj (study or studies)).tw. 
15. (cross sectional adj (study or studies)).tw. 
16. or/1-5,8-15 
17. kyphoplasty/ or percutaneous vertebroplasty/ or cementoplasty/ 
18. (kyphoplasty or cementoplasty or vertebroplasty or sacroplasty).tw. 
19. exp Bone Cement/ 
20. bone cement*.tw. 
21. 17 or 18 or 19 or 20 
22. exp neoplasm/ 
23. (cancer* or carcin* or neoplas* or oncolog* or malignan*or metast* or tumour* or tumor* or 
myeloma*).tw. 
24. Spine Fracture/ 
25. ((spine or spinal) and (fracture* or neoplas* or cancer* or carcin* or oncolog* or malignan* or 
metast* or tumour* or tumor or myeloma*)).tw. 
26. osteoporosis/ 
27. osteoporotic.tw. 
28. 25 or 22 or 24 or 23 or 26 or 27 
29. 21 and 28 and 16 
30. limit 29 to human 
31. limit 30 to english language 
 
Embase (RCT) Search Strategy  
1. Clinical trial/ 
2. Randomized controlled trial/ 
3. Randomization/ 
4. Single blind procedure/ 
5. Double blind procedure/ 
6. Crossover procedure/ 
7. Placebo/ 
8. Randomi?ed controlled trial$.tw. 
9. Rct.tw. 
10. Random allocation.tw. 
11. Randomly allocated.tw. 
12. Allocated randomly.tw. 
13. (allocated adj2 random).tw. 
14. Single blind$.tw. 
15. Double blind$.tw. 
16. ((treble or triple) adj blind$).tw. 
17. Placebo$.tw. 
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18. Prospective study/ 
19. or/1-18 
20. kyphoplasty/ or percutaneous vertebroplasty/ or cementoplasty/ 
21. (kyphoplasty or cementoplasty or vertebroplasty or sacroplasty).tw. 
22. exp Bone Cement/ 
23. bone cement*.tw. 
24. 20 or 21 or 22 or 23 
25. exp neoplasm/ 
26. (cancer* or carcin* or neoplas* or oncolog* or malignan*or metast* or tumour* or tumor* or 
myeloma*).tw. 
27. Spine Fracture/ 
28. ((spine or spinal) and (fracture* or neoplas* or cancer* or carcin* or oncolog* or malignan* or 
metast* or tumour* or tumor* or myeloma*)).tw. 
29. osteoporosis/ 
30. osteoporotic.mp. 
31. 27 or 25 or 28 or 26 or 29 or 30 
32. 24 and 19 and 31 
33. limit 32 to humans 
34. limit 33 to english language 
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Appendix 3: Raw data from the study 
Survival Data on patients with Spinal Metastases 
Survival Data on patients with Myeloma 
VAS raw data 
Roland-Morris raw data 
Kaplan Meier Survival Function data 
EQ-5D values raw data 
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Raw patient data ( including survival) on patients with spinal metastases 
Case no.  Date VP  Alive/Dead Survival  Primary cancer 
     (1/0)  (months) 
--------------------------------------------------------------------------------------------------------------------- 
 
 
                      
 
1. 22.4.2001 1 107 
 
Breast 
2. 1.8.2001 0 1 
 
Unknown 
3. 12.9.2001 1 105 
 
Seminoma 
4. 23.2.2002 0 11 
 
Breast 
5. 17.2.2002 0 2 
 
? 
6. 24.12.2002 1 90 
 
Breast 
7. 29.1.2003 0 20 
 
Breast 
8. 27.7.2003 0 7 
 
Lung 
9. 22.4.2003 0 18 
 
? 
10. 20.5.2003 0 0.7 
 
Breast 
11. 29.7.2003 0 7 
 
Prostate 
12. 13.1.2004 0 6 
 
Breast 
13. 9.6.2004 0 5 
 
Lung 
14. 17.10.2004 0 24 
 
? 
15. 9.12.2004 0 16 Failed  Breast 
16. 16.12.2004 1 66 
 
Renal 
17. 10.2.2005 0 0.6 
 
? 
18. 31.3.2005 0 3 
 
Rectal 
19. 24.6.2005 1 60 
 
Lymphoma 
20. 15.7.2005 0 3 
 
Lung 
21. 22.11.2005 0 47 
 
Breast 
22. 22.12.2005 1 54 
 
Seminoma 
23. 18.1.2006 0 33 
 
Breast 
24. 18.1.2006 0 14 
 
? 
25. 23.2.2006 1 52 
 
Breast 
26. 9.3.2006 1 51 
 
Breast 
27.  11.4.2006 0 2 
 
Waldenstorm 
28. 5.7.2006 0 2 
 
Adeno? 
29. 31.7.2006 0 2 
 
? 
30. 14.8.2006 0 17 
 
Colon 
31. 21.12.2006 0 31 
 
Breast 
32. 15.2.2007 0 3 
 
Lung 
33. 23.12.2007 1 40 
 
Lymphoma 
34. 15.3.2007 1 39 
 
Lymphoma 
35. 15.3.2007 0 3 
 
Oesophagus 
36. 23.3.2007 0 1 
 
Cervix 
37. 8.6.2007 0 10 
 
Breast 
38. 11.6.2007 0 2 
 
Melanoma 
39. 20.6.2007 0 5 
 
Tongue 
40. 20.7.2007 0 0.5 
 
Lung 
41. 7.9.2007 0 0.7 
 
Lung 
42. 10.9.2007 0 1 
 
Lymphoma 
43. 2.11.2007 0 8 
 
Breast 
44. 29.4.2008 0 5 
 
Lung 
45. 1.5.2008 0 0.3 
 
Prostate 
46. 15.7.2008 0 12 
 
Breast 
47. 14.8.2007 1 33 22 Lymphoma 
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48. 22.4.2008 1 26 
 
Breast 
49. 5.8.2008 1 22 
 
Breast 
50. 15.8.2008 1 22 
 
Lymphoma 
51. 16.9.2008 0 4 
 
Lung 
52. 2.12.2008 1 18 
 
Renal 
53. 10.3.2008 0 2 
 
? 
54. 19.8.2008 1 22 
 
Breast 
55. 14.12.2008 0 1 
 
Renal 
56. 4.12.2009 0 1 
 
Renal 
57. 2.11.2007 0 8 
 
Breast 
58. 7.11.2008 0 16 
 
Lymphoma 
59. 15.10.2008 0 8 
 
Oesophagus 
60. 8.1.2009 0 1 
 
Breast 
61. 9.1.2009 0 1 
 
Oesophagus 
62. 13.1.2009 0 2 
 
Prostate/Bladder 
63. 29.1.2009 0 7 
 
Renal 
64. 3.2.2009 0 6 
 
Bladder 
65. 6.5.2009 1 13 
 
Lymphoma 
66. 2.5.2009 1 13 
 
Renal 
67. 26.5.2009 1 13 
 
Lung 
68. 1.6.2009 1 12 
 
Lung 
69. 1.6.2009 0 0.3 
 
Prostate 
70. 1.7.2009 1 11 
 
Lymphoma 
71. 1.7.2009 1 11 
 
Renal 
72. 1.7.2009 0 4 
 
Rectal 
73. 1.8.2009 0 7 
 
Lung 
74. 20.10.2009 0 3 
 
Prostate 
75. 20.10.2009 1 8 
 
Renal 
76. 9.10.2009 1 8 
 
Lung 
77. 13.10.2009 1 8 
 
Breast 
78.  18.11.2009 1 7 
 
Breast 
79. 26.11.2009 1 7 
 
AML 
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Survival data on patients with Myeloma. 
Case no.   Alive/   Follow up 
Dead (months) 
1.    0  24 died 130603 
2.    0  55 3 
3.    1  91  
4.    1  87  
5.    1  74  
6.    0  16 died 201104 
7.    1  69  
8.    0  57 3 
9.    0  7  
10.    0  46  
11.    0  16  
12.    1  58  
13.    1  55  
14.    0  31  
15.    0  17 16 
16.    0  2  
17.    1  48  
18.    1  36  
19.    1  35  
20.    0  9 1 
21.    1  34  
22.    1  29  
23.    0  13  
24.    1  20  
25.    1  20  
26.    1  19  
27.    1  18  
28.    0  10  
29.    1  40  
30.    1  47  
31.    1  7  
32.    1  10  
33.    1  7  
34.    1  9  
35.    1  10  
36.    1  12  
37.    1  15  
38.    0  17  
39.    0  37  
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VAS Raw Data: 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                  Pre        Post 
6 4 
7 2 
7 5 
10 9 
7 2 
9 7 
9 9 
10 8 
7 3 
5 5 
5 3 
3 6 
5 1 
7 0 
5 0 
8 7 
9 7 
4 2 
8 7 
10 4 
10 5 
8 5 
5 1 
8 2 
10 8 
7 8 
8 8 
5 6 
9 3 
10 6 
10 6 
6 7 
8 5 
8 9 
9 7 
10 8 
7 2 
8 3 
8 2 
5 3 
10 2 
8 8 
7 8 
8 7 
8 4 
9 0 
5 3 
10 4 
6 3 
Mean7.571429 4.77551 
SD1.881932 2.671339 
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Roland-Morris Raw Data: 
Pre  Post 
20 11 
19 23 
10 19 
23 13 
20 7 
22 7 
23 10 
19 20 
17 23 
22 18 
16 0 
8 8 
19 18 
21 10 
16 8 
23 9 
13 13 
24 23 
23 22 
21 19 
19 18 
15 18 
7 6 
24 16 
21 14 
23 5 
16 19 
7 14 
12 1 
23 17 
21 14 
24 23 
16 22 
18 10 
20 0 
21 19 
22 15 
17 1 
Mean18.55263 13.5 
SD 4.791306 6.946708 
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Kaplan Meier Survival Function Data 
 
Kaplan Meier Survival Numbers: 
Myeloma: 
  6mth  1y  2y  3y  4y  5y 
No. at risk 38/39  30/33  18/24  13/14  8/10  4/6 
 
KM estimate 0.97  0.88  0.66  0.62  0.49  0.33 
 
Mets : 
No. at risk 47/79  28/38  18/25  12/14  8/9  7/7 
KM estimate 0.59  0.44  0.32  0.27  0.24  0.24 
 
At 4  years  - 8 long term survivals: 
4 breast cancer 
2 seminoma  
1 renal carcinoma  
1 lymphoma 
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Case Processing Summary 
Total N N of Events 
Censored 
N Percent 
79 52 27 34.2% 
 
 
Myeloma Kaplan Meier Survival Curve 
Case Processing Summary 
Total N N of Events 
Censored 
N Percent 
39 15 24 61.5% 
 
 
Case Processing Summary 
Group Total N N of Events 
Censored 
N Percent 
mets 79 52 27 34.2% 
myeloma 39 15 24 61.5% 
Overall 118 67 51 43.2% 
 
 
 
 
 
Survival Table 
Group Time Status 
Cumulative Proportion Surviving at 
the Time N of Cumulative 
Events 
N of Remaining 
Cases Estimate Std. Error 
mets 1 .300 dead . . 1 78 
2 .300 dead .975 .018 2 77 
3 .500 dead .962 .022 3 76 
4 .600 dead .949 .025 4 75 
5 .700 dead . . 5 74 
6 .700 dead .924 .030 6 73 
7 1.000 dead . . 7 72 
8 1.000 dead . . 8 71 
9 1.000 dead . . 9 70 
10 1.000 dead . . 10 69 
11 1.000 dead . . 11 68 
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12 1.000 dead . . 12 67 
13 1.000 dead .835 .042 13 66 
14 2.000 dead . . 14 65 
15 2.000 dead . . 15 64 
16 2.000 dead . . 16 63 
17 2.000 dead . . 17 62 
18 2.000 dead . . 18 61 
19 2.000 dead . . 19 60 
20 2.000 dead .747 .049 20 59 
21 3.000 dead . . 21 58 
22 3.000 dead . . 22 57 
23 3.000 dead . . 23 56 
24 3.000 dead . . 24 55 
25 3.000 dead .684 .052 25 54 
26 4.000 dead . . 26 53 
27 4.000 dead .658 .053 27 52 
28 5.000 dead . . 28 51 
29 5.000 dead . . 29 50 
30 5.000 dead .620 .055 30 49 
31 6.000 dead . . 31 48 
32 6.000 dead .595 .055 32 47 
33 7.000 dead . . 33 46 
34 7.000 dead . . 34 45 
35 7.000 dead . . 35 44 
36 7.000 dead .544 .056 36 43 
37 7.000 alive . . 36 42 
38 7.000 alive . . 36 41 
39 8.000 dead . . 37 40 
40 8.000 dead . . 38 39 
41 8.000 dead .504 .056 39 38 
42 8.000 alive . . 39 37 
43 8.000 alive . . 39 36 
44 8.000 alive . . 39 35 
45 10.000 dead .490 .057 40 34 
46 11.000 dead .476 .057 41 33 
47 11.000 alive . . 41 32 
48 11.000 alive . . 41 31 
49 12.000 dead .460 .057 42 30 
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50 12.000 alive . . 42 29 
51 13.000 alive . . 42 28 
52 13.000 alive . . 42 27 
53 13.000 alive . . 42 26 
54 14.000 dead .443 .057 43 25 
55 16.000 dead . . 44 24 
56 16.000 dead .407 .058 45 23 
57 17.000 dead .389 .058 46 22 
58 18.000 dead .372 .058 47 21 
59 18.000 alive . . 47 20 
60 20.000 dead .353 .058 48 19 
61 22.000 alive . . 48 18 
62 22.000 alive . . 48 17 
63 22.000 alive . . 48 16 
64 24.000 dead .331 .059 49 15 
65 26.000 alive . . 49 14 
66 31.000 dead .307 .059 50 13 
67 33.000 dead .284 .059 51 12 
68 33.000 alive . . 51 11 
69 39.000 alive . . 51 10 
70 40.000 alive . . 51 9 
71 47.000 dead .252 .060 52 8 
72 51.000 alive . . 52 7 
73 52.000 alive . . 52 6 
74 54.000 alive . . 52 5 
75 60.000 alive . . 52 4 
76 66.000 alive . . 52 3 
77 90.000 alive . . 52 2 
78 105.000 alive . . 52 1 
79 107.000 alive . . 52 0 
myeloma 1 2.000 dead .974 .025 1 38 
2 7.000 dead .949 .035 2 37 
3 7.000 alive . . 2 36 
4 7.000 alive . . 2 35 
5 9.000 dead .922 .043 3 34 
6 9.000 alive . . 3 33 
7 10.000 dead .894 .050 4 32 
8 10.000 alive . . 4 31 
9 10.000 alive . . 4 30 
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10 12.000 alive . . 4 29 
11 13.000 dead .863 .057 5 28 
12 15.000 alive . . 5 27 
13 16.000 dead . . 6 26 
14 16.000 dead .799 .069 7 25 
15 17.000 dead . . 8 24 
16 17.000 dead .735 .077 9 23 
17 18.000 alive . . 9 22 
18 19.000 alive . . 9 21 
19 20.000 alive . . 9 20 
20 20.000 alive . . 9 19 
21 24.000 dead .696 .082 10 18 
22 29.000 alive . . 10 17 
23 31.000 dead .655 .087 11 16 
24 34.000 alive . . 11 15 
25 35.000 alive . . 11 14 
26 36.000 alive . . 11 13 
27 37.000 dead .605 .093 12 12 
28 40.000 alive . . 12 11 
29 46.000 dead .550 .100 13 10 
30 47.000 alive . . 13 9 
31 48.000 alive . . 13 8 
32 55.000 dead .481 .108 14 7 
33 55.000 alive . . 14 6 
34 57.000 dead .401 .116 15 5 
35 58.000 alive . . 15 4 
36 69.000 alive . . 15 3 
37 74.000 alive . . 15 2 
38 87.000 alive . . 15 1 
39 91.000 alive . . 15 0 
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EQ-5D Values: 
Pre – VP Post VP 
0.55 1 
0.024 -0.181 
0.62 0.727 
0.088 0.159 
0.088 0.362 
0.055 0.516 
0.76 0.691 
1 0.796 
0.62 0.812 
0.587 0.516 
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